Self-assembled ferritin nanoantigen particles and influenza vaccine and preparation method

CN115160442A8Active Publication Date: 2024-11-26THE INST OF BIOTECHNOLOGY OF THE CHINESE ACAD OF AGRI SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210691318.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2019-04-16
Publication Date
2024-11-26
Estimated Expiration
2039-04-16

AI Technical Summary

Technical Problem

Existing influenza vaccines need to be frequently redesigned because the surface antigen of influenza A virus is prone to antigenic drift and antigenic switching, and attenuated strain vaccines have the risk of restoring virulence in susceptible groups, making it difficult to provide safe, efficient and cheap genes. Engineered vaccine solutions.

Method used

Self-assembled ferritin nanoantigen particles are used to fuse the influenza virus hemagglutinin protein with ferritin subunits, and the expression amount and efficiency are improved through gene mutation optimization. The silkworm expression system and baculovirus vector are used to construct a recombinant vaccine to achieve the goal in animals. Induces antibody responses in vivo.

Benefits of technology

It provides a broad-spectrum and highly efficient influenza vaccine that can be produced quickly and on a large scale without involving live harmful viruses, induces high levels of anti-influenza antibodies, improves immune efficacy and immunity range, and is safe and easy to operate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115160442A8_ABST
    Figure CN115160442A8_ABST
Patent Text Reader

Abstract

The present invention discloses self-assembled ferritin nanoantigen particles and influenza vaccines and preparation methods. The present invention fuses the extracellular domain of influenza virus hemagglutinin protein with the N-terminus of the subunit of self-assembled ferritin nanoparticles, and displays the influenza virus hemagglutinin protein on the surface of the self-assembled ferritin cage structure. The present invention performs mutation optimization on the influenza virus hemagglutinin protein to improve its soluble expression amount and expression efficiency, improve the immune efficacy and breadth of the vaccine, and improve the immunogenicity of the influenza virus hemagglutinin protein. The present invention utilizes Escherichia coli prokaryotic expression system, silkworm and AcMNPV-insect cell eukaryotic expression system to express and prepare recombinant protein vaccines respectively, or uses recombinant baculovirus to present genes in vertebrate body tissues to produce antigen-induced antibody production. The influenza vaccine of the present invention can induce broadly neutralizing anti-influenza antibodies, which can not only improve the immune efficacy but also expand the immune range, and has the potential of a universal vaccine with cross-immunity efficacy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with application number "201910302335.1", application date "April 16, 2019", and invention title "Influenza Vaccine and Preparation Method Based on Self-Assembled Ferritin Nanoantigen Particles". Technical Field

[0002] This invention relates to self-assembled ferritin nanoantigen particles, and more particularly to nanoantigen particles comprising influenza virus hemagglutinin protein and monomeric ferritin subunits fused together, and influenza vaccines prepared from the nanoparticle antigens, belonging to the field of influenza vaccines. Background Technology

[0003] Influenza (flu) is an acute respiratory infectious disease caused by the influenza virus. Influenza viruses are highly contagious, have a high incidence rate, and a wide reach, severely impacting human health and the global economy. Influenza viruses are classified into three types: A, B, and C. The bovine influenza virus, discovered in recent years, is classified as type D. Type A influenza viruses frequently undergo antigenic mutation, causing several global influenza pandemics. The best tool for preventing and controlling influenza viruses is primarily vaccines. Currently used influenza vaccines mainly work by inducing the body to produce protective antibodies against the influenza virus surface antigens hemagglutinin (HA) and neuraminidase (NA). However, type A influenza viruses are prone to antigenic drift and antigenic switching, necessitating periodic redesign of vaccines to adapt to the viruses most likely to cause influenza in the following year. Given current trends in influenza virus prevention and control, the development of a universal vaccine with broad-spectrum and highly effective immunity is urgently needed. Prevention is the best treatment for any disease, and vaccines, which target various diseases, are the main force in this preventative measure. Traditional vaccines are mostly live attenuated vaccines, including naturally attenuated strains and recombinant attenuated strains. The biggest drawback of using attenuated vaccines is the risk of reversion to virulence in susceptible populations. Therefore, the production of safe, effective, and inexpensive genetically engineered vaccines has become a new demand. Ferritin nanoparticles, self-assembled from 24 subunits, provide an ideal platform for antigen presentation and vaccine development.

[0004] In recent years, ferritin has been applied as a nanomaterial in various fields. Ferritin is a cage-like protein widely found in organisms. Its protein shell is composed of 24 ferritin subunits, with each three subunits forming a trimer subunit. The N-terminus of ferritin extends to the outer surface, making it easy to modify genetically and fuse with protein peptides. Highly ordered repetitive antigens distributed at 5-10 nm intervals on the surface of microorganisms readily induce strong T cell-dependent antibody responses. Ferritin is very stable, tolerating high temperatures (70-80℃) and various denaturing agents without affecting its native protein structure. Ferritin is pH sensitive; under acidic conditions (pH 2.0), the protein shell disintegrates, while when the pH returns to physiological conditions (pH 7.0), the disintegrated protein subunits can reassemble into complete ferritin. In recent years, research on ferritin has mainly focused on: (1) modifying the inner surface of ferritin to encapsulate specific drugs or promote the synthesis of nanomaterials; (2) modifying the outer surface of ferritin and linking it with PEG or antibodies to expand new functions; and (3) controlling the self-assembly of ferritin through modification of the outer surface or inter-subunit contact surfaces. Ferritin nanoparticles can display antigens and significantly enhance the immunogenicity of antigens, causing stronger humoral and cellular immune responses. Therefore, ferritin is an ideal nanovaccine platform. Summary of the Invention

[0005] One objective of this invention is to provide a self-assembled ferritin nanoantigen particle containing a fusion protein;

[0006] The second objective of this invention is to mutate the fusion protein to increase its expression level or expression efficiency.

[0007] The third objective of this invention is to provide a nanoparticle influenza vaccine based on self-assembled ferritin nanoantigen particles;

[0008] The fourth objective of this invention is to provide a method for efficiently expressing the fusion protein;

[0009] The fifth objective of this invention is to provide a method for presenting a fusion gene constructed from self-assembled ferritin nanoparticles and hemagglutinin protein into an animal and inducing antibody production by presenting an antigen in the animal.

[0010] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0011] The present invention first provides a nanoantigen particle containing a fusion protein, wherein the fusion protein is obtained by linking the N-terminus of an influenza virus hemagglutinin protein and a monomeric ferritin subunit;

[0012] The monomeric ferritin subunit includes any one of bacterial ferritin, plant ferritin, algal ferritin, insect ferritin, fungal ferritin, or mammalian ferritin; preferably, the monomeric ferritin subunit is Helicobacter pylori ferritin monomer, whose amino acid sequence is shown in SEQ ID NO.1, and whose encoding gene nucleotide sequence is shown in SEQ ID NO.2.

[0013] The influenza virus hemagglutinin protein is either the H9 influenza virus hemagglutinin protein or the H5 influenza virus hemagglutinin protein; preferably, the selected region of the influenza virus hemagglutinin protein includes regions selected from the following: regions that allow the formation of hemagglutinin trimers, stem regions, and extracellular domains; most preferably, the H9 influenza virus hemagglutinin protein is selected only from the specific site of the extracellular domain of the H9 influenza virus hemagglutinin protein, and the H5 influenza virus hemagglutinin protein is selected only from the specific site of the extracellular domain of the H5 influenza virus hemagglutinin protein.

[0014] The amino acid sequence of the H9 influenza virus hemagglutinin protein is shown in SEQ ID NO.3; the amino acid sequence of the H5 influenza virus hemagglutinin protein is shown in SEQ ID NO.5.

[0015] Preferably, the fusion protein is obtained by linking the N-terminus of the influenza virus hemagglutinin protein and the monomeric ferritin subunit via the linker peptide SGG.

[0016] The amino acid sequence of one fusion protein provided by the present invention is shown in SEQ ID NO.7 (H9 HA-Ferritin), and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.8; the amino acid sequence of another fusion protein provided by the present invention is shown in SEQ ID NO.9 (H5 HA-Ferritin), and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.10.

[0017] To improve the expression level of the fusion protein obtained by linking influenza virus hemagglutinin protein with ferritin monomers, this invention further optimizes the mutagenic sequences of the fusion proteins shown in SEQ ID NO.7 and SEQ ID NO.9 through mutation, and performs glycosylation site analysis after sequence optimization to eliminate glycosylation sites and increase soluble expression. Therefore, after optimizing the homologous sequence, single-site mutations, two-site mutations, and multi-site mutations are performed on amino acids to improve its soluble expression level and expression efficiency.

[0018] Specifically, the inventors analyzed the amino acid sequences of hemagglutinin proteins from 20 recent H5 and H9 strains circulating in different regions to identify the most universally recognized sequence, which was then used as the antigen gene for the corresponding strain to achieve the best protective effect. Based on this, the invention further utilizes OptimumGene... TM The technology optimizes the amino acid sequences of H5 and H9 hemagglutinin proteins. The optimized amino acid sequences of the hemagglutinin protein and ferritin monomer subunits are then modified according to the codon bias of *E. coli*. Various parameters affecting gene transcription efficiency, translation efficiency, and protein folding, such as GC content, CpG dinucleotide content, codon bias, mRNA secondary structure, mRNA free energy stability, RNA instability gene sequences, and repetitive sequences, are optimized while maintaining the final translated protein sequence unchanged. Furthermore, to improve ferritin expression and soluble expression, a point mutation N19Q is performed on the ferritin monomer subunit. Finally, the optimized amino acid sequence of the fusion protein shown in SEQ ID NO. 7, obtained through the above optimization method, is shown in SEQ ID NO. 11, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO. 12; the optimized amino acid sequence of the fusion protein shown in SEQ ID NO. 9, obtained through the above optimization method, is shown in SEQ ID NO. 13, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO. 14.

[0019] The present invention expresses the optimized codon-optimized sequence in the silkworm expression system. According to the ELISA titer results of the gene expression product, the expression level of the codon-optimized codon-optimized sequence is significantly improved compared with that before optimization.

[0020] This invention obtained H9 HA-Ferritin-C and H5 HA-Ferritin-C mutants. Using the codon-optimized gene sequences of the H9 HA-Ferritin-C and H5 HA-Ferritin-C mutants as templates, multiple primer pairs were designed to perform site-directed mutagenesis on conserved sequences.

[0021] Multiple unit point mutants were obtained by mutating the amino acid sequence shown in SEQ ID NO.11 using the amino acid unit point mutation method of N40S, N41D, A47T, L51I, M58I, G63N, P83L, P101S, T138K, E181G, N191H, H192Q, D196E, T197A, G236R, I267V, Q304H, D367N, N419S or V469M.

[0022] Multiple unit point mutants were obtained by performing unit point mutations on the amino acid sequence shown in SEQ ID NO.13 using the amino acid unit point mutation methods of V40I, K51R, T52A, K56R, S72R, N100S, H126R, G155E, E186K, D187N, V190I, L191M, G193W, I242M, N289Y, N325S, Y366F, E406G, D462E or Q501H.

[0023] In this invention, these single-point mutants were expressed in a silkworm expression system. According to the expression results, the titers of the expression products of the six mutants obtained by single-point mutation of the amino acid sequence shown in SEQ ID NO.11 using the amino acid single-point mutation methods of N40S, N41D, A47T, N191H, H192Q or D196E were significantly improved.

[0024] The expression products of six mutants obtained by point mutation of the amino acid sequence shown in SEQ ID NO.13 using the amino acid unit point mutation method of V40I, K51R, K56R, V190I, L191M or G193W showed a significant increase in titer.

[0025] Based on the fact that the identified partial site mutations are effective mutations, the expression levels of H9 HA-Ferritin-COM and H5 HA-Ferritin-COM mutants can be increased. Considering that the amino acid sequence is the primary structure of a protein and determines its higher-order structure, and that some of the above-mentioned single-site amino acid mutations may be interrelated, this invention further performs double-site amino acid mutations. This invention combines the single-mutation sites that can increase expression levels—H9 HA: N40S, N41D, A47T, N191H, H192Q, or D196E; and H5 HA: V40I, K51R, K56R, V190I, L191M, or G193W—in pairs for double-site mutations, as follows:

[0026] Fifteen two-site mutants were obtained by mutating the amino acid sequence shown in SEQ ID NO.11 at two sites: N40S-N41D, N40S-A47T, N40S-N191T, N40S-H192Q, N40S-D196E, N41D-A47T, N41D-N191H, N41D-H192Q, N41D-D196E, A47T-N191H, A47T-H192Q, A47T-D196E, N191H-H192Q, N191H-D196E, or H192Q-D196E.

[0027] Fifteen site mutants were obtained by performing two-site mutations of the amino acid sequence shown in SEQ ID NO.13: V40I-K51R, V40I-K56R, V40I-V190I, V40I-L191M, V40I-G193W, K51R-K56R, K51R-V190I, K51R-L191M, K51R-G193W, K56R-V190I, K56R-L191M, K56R-G193W, V190I-L191M, V190I-G193W, or L191M-G193W.

[0028] In this invention, 30 two-site mutants were expressed in a silkworm expression system. The expression results showed that the expression products of three mutants obtained by two-site mutations of the amino acid sequence shown in SEQ ID NO. 11 (N40S-N41D, N41D-A47T, or A47T-H192Q) exhibited significantly increased titers. Among these, the mutant obtained by two-site mutations of the amino acid sequence shown in SEQ ID NO. 11 (N41D-A47T) (the amino acid sequence of which is shown in SEQ ID NO. 19, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO. 20) showed the most significant titer increase.

[0029] The expression products of three site mutants obtained by two-site mutations of the amino acid sequence shown in SEQ ID NO.13, namely V40I-K51R, K51R-V190I, or V190I-G193W, showed a significant increase in titer. Among them, the site mutant obtained by two-site mutations of the amino acid sequence shown in SEQ ID NO.13, namely V190I-G193W (the amino acid sequence of the mutant is shown in SEQ ID NO.21, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.22), showed the most significant increase in titer.

[0030] Given that some two-site mutations can effectively increase expression levels and titers, and considering that the amino acid sequence is the primary structure of a protein and determines its higher-order structure, it is speculated that this may be due to the proximity and correlation of some mutation sites in the single-site mutations. Therefore, this invention further attempts to perform multi-site amino acid mutations. By analyzing glycosylation sites, this invention found that six single-mutation sites can effectively increase the expression level of the target gene. Therefore, multi-site mutation is based on obtaining effective two-site mutation sequences, and site-directed mutagenesis at multiple mutation sites is performed using fusion PCR. The specific mutation methods are as follows:

[0031] A multi-site mutant was obtained by multi-site mutation of the amino acid sequence shown in SEQ ID NO. 11 using the N40S-N41D-A47T-N191H-H192Q-D196E amino acid sequence. The amino acid sequence of the multi-site mutant is shown in SEQ ID NO. 23, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO. 24. A multi-site mutant was obtained by multi-site mutation of the amino acid sequence shown in SEQ ID NO. 13 using the V40I-K51R-K56R-V190I-L191M-G193W amino acid sequence. The amino acid sequence of the multi-site mutant is shown in SEQ ID NO. 25, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO. 26.

[0032] This invention expresses two multi-site mutants (SEQ ID NO.23 and SEQ ID NO.25) in a silkworm expression system. The expression results show that the expression levels of the two multi-site mutants are significantly higher than those of the single and double mutants mentioned above. Furthermore, the expression products of these two multi-site mutants in the silkworm expression system are preliminarily purified and observed under an electron microscope. The observation results show that the product consists of nanoparticles of the expected size, with cage-like structures approximately 12 nanometers in diameter, and antenna-like protrusions are visible upon close observation.

[0033] In this invention, the encoding genes of two multi-site mutants (SEQ ID NO.23, SEQ ID NO.25) were cloned into a mammalian baculovirus expression vector to construct a recombinant baculovirus that presents the gene. The recombinant baculovirus was presented to mice and chickens, and the results showed that the antibody titers produced by the mice and chickens were significantly higher than those of healthy silkworm pupae and traditional vaccines.

[0034] Therefore, the self-assembled ferritin nanoantigen particles containing fusion proteins provided by this invention can be used to prepare influenza vaccines, and the application method includes:

[0035] (I) The fusion protein encoding gene is expressed in prokaryotic cells using a prokaryotic system to obtain nanoantigen particles. The expressed nanoantigen particle product is purified and mixed with a medically acceptable immune adjuvant or carrier to obtain an influenza vaccine.

[0036] For reference, the steps for expressing nanoantigen particles in prokaryotic cells using a prokaryotic expression system include:

[0037] (1) The original sequence or the mutated optimized sequence of the fusion protein was cloned into the expression vector pET28a to obtain the recombinant plasmids pET28a-H9 HA-Ferritin and pET28a-H5 HA-Ferritin;

[0038] (2) The recombinant plasmids pET28a-H9 HA-Ferritin and pET28a-H5 HA-Ferritin were transformed into BL21(DE3) competent cells for expression, and then purified by nickel column chromatography.

[0039] (II) The fusion protein encoding gene is expressed in eukaryotic cells using a eukaryotic expression system. The expressed antigen product is then purified and mixed with a medically acceptable immune adjuvant or vector to obtain an influenza vaccine.

[0040] For reference, the method for expressing the fusion protein-encoding gene in eukaryotic cells using a eukaryotic expression system includes: expressing the fusion protein-encoding gene in a silkworm expression system, collecting and purifying the expressed antigen; preferably, constructing the fusion protein-encoding gene into a silkworm baculovirus to prepare a recombinant silkworm baculovirus; and amplifying the recombinant silkworm baculovirus in silkworm cells and expressing it in silkworms or silkworm pupae.

[0041] Alternatively, the fusion protein encoding gene can be expressed in the AcMNPV-insect cell eukaryotic expression system, and the expressed antigen can be collected and purified; preferably, the fusion protein encoding gene can be cloned into a baculovirus transfer vector to construct a recombinant baculovirus transfer vector; the recombinant baculovirus transfer vector and baculovirus DNA can be co-transfected into insect cells to obtain recombinant baculovirus; the recombinant baculovirus can be used to infect insect hosts or insect cells, and the infected insect cells or insect hosts can be cultured to express the corresponding antigen, and then purified to obtain the final product;

[0042] (III) The fusion protein encoding gene can also be cloned into a gene presenting vector to construct a recombinant baculovirus transfer vector that presents exogenous genes to vertebrate cells or individuals. The recombinant baculovirus transfer vector is transfected into silkworm cells to obtain recombinant virus. The obtained recombinant virus presents antigens in animals and induces the animals to produce antibodies by injection or oral administration.

[0043] The present invention further provides a vaccine for the prevention and treatment of influenza, comprising: a preventive or therapeutically effective amount of self-assembled ferritin nanoantigen particles containing a fusion protein and a pharmaceutically acceptable immune adjuvant or carrier.

[0044] The vaccines of the present invention can be formulated with a variety of different pharmaceutical excipients or carriers. These may include salts and buffers to provide physiological ionic strength and pH, surfactants such as polysorbate 20 and 80 to prevent antigen aggregation, stabilizers for antigen stabilization such as PEG, trehalose, and gelatin, and polymers for sustained release such as CMC, HEC, and dextran. The vaccines can also be formulated with controlled release or enhanced display systems such as hydrogels, virions, nanoparticles, and emulsions. The vaccines can also be formulated with adjuvants to further enhance cross-reactive immune responses and cross-protection; suitable adjuvants may be selected from polysaccharides such as lipopolysaccharides and saponins, nucleic acids such as CpG and polyI:C, lipids such as MPL (monophosphoryllipid A), proteins such as bacterial flagellin, inorganic salts such as aluminum salts and calcium phosphate, emulsions such as Freund's incomplete adjuvant, MF59 and AS03, and various Toll-like receptor ligands. Different adjuvants can be tested with the treated antigen to identify suitable adjuvants that produce high levels of cross-reactive immune responses and cross-protection at appropriate adjuvant doses, including complete or 100% protection.

[0045] The influenza vaccine of the present invention can be used through various routes, such as intramuscular, subcutaneous, intranasal, local, sublingual, or oral administration.

[0046] The vaccine provided by this invention can induce broadly neutralizing influenza antibodies by displaying the influenza virus protein trimer structure on the surface of the ferritin cage structure of Helicobacter pylori. The neutralizing antibodies induced by this vaccine not only increase immunogenicity but also broaden the range of immunity, providing immunity against both homologous and heterologous influenza viruses from different years.

[0047] Compared with the prior art, the present invention has the following advantages and effects:

[0048] 1. This invention utilizes the prokaryotic expression system of Escherichia coli, silkworm baculovirus and AcNPV-insect cell eukaryotic expression system to express recombinant protein vaccines. The vaccine preparation process does not involve live harmful viruses, and is safer and simpler than the traditional method of preparing influenza vaccines using chicken embryos, making it suitable for rapid large-scale production.

[0049] 2. The nano-influenza vaccine provided by this invention can induce influenza antibodies with broad-spectrum properties, laying the foundation for the preparation of a universal influenza vaccine.

[0050] 3. The nano-influenza vaccine provided by this invention induces significantly higher levels of anti-influenza antibodies in animals immunized with this nano-influenza vaccine compared to traditional vaccines.

[0051] Definitions of terms involved in this invention

[0052] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0053] The terms "antigen" and "immunogen" are used interchangeably and refer to molecules, substances, proteins, glycoproteins, or live viruses that can induce specific humoral (antibody) and cellular immune responses.

[0054] The term "antigenicity" refers to the ability of an antibody to react with or bind to a specific antigen; the term "immunogenicity" refers to the ability of an antigen or vaccine to induce a specific immune response; the term "immune response" refers to a humoral or antibody-mediated and cell-mediated immune response against an antigen, vaccine, or infectious agent; the term "vaccine" refers to a composition comprising an antigen used for therapeutic treatment or prophylactic immunization against an infectious or non-infectious disease; the term "immunity" refers to the immune response generated by vaccination or infection that provides protection against infectious or foreign agents; the term "recombinant protein or antigen" refers to a protein or antigen produced using recombinant DNA technology, which can be used to clone and express genes in a variety of hosts, including bacteria, mammalian cells, insect cells, and plants, to produce proteins. The term "potency" refers to the amount of antigen in an antigen preparation or vaccine as measured by a specified potency assay.

[0055] The terms “mutation” and “mutant” have their common meanings here, referring to genetic, naturally occurring or introduced changes in a nucleic acid or polypeptide sequence, and their meanings are the same as those commonly known to those skilled in the art.

[0056] The terms "host cell" or "recombinant host cell" refer to a cell containing the polynucleotides of the present invention, regardless of the method used for insertion to produce a recombinant host cell, such as direct uptake, transduction, f-pairing, or other methods known in the art. The exogenous polynucleotides may remain as, for example, non-integrating vectors of plasmids or may be integrated into the host genome.

[0057] The term "transfection" refers to the process by which eukaryotic cells acquire new genetic markers due to the incorporation of foreign DNA. Attached Figure Description

[0058] Figure 1 A schematic diagram of the hemagglutination assay of the H9 HA-Ferritin-CO-M6 expression product in the silkworm expression system; the initial dilution was 100-fold, and the hemagglutination value reached 51200.

[0059] Figure 2 A schematic diagram of the hemagglutination assay of the H5 HA-Ferritin-CO-M6 expression product in the silkworm expression system; the initial dilution was 400 times, and the hemagglutination value reached 12800.

[0060] Figure 3 Virus neutralization experiment diagrams. In diagram A, the neutralizing antibody inhibits the virus, showing normal cell growth; in diagram B, some cells are infected with the virus, showing cells in a shrunken state after infection.

[0061] Figure 4 Western blotting detection image of H9 HA-Ferritin-CO-M6 expression product in silkworm expression system; A is the silkworm expression product of H9 HA-Ferritin-CO-M6; B is the negative control.

[0062] Figure 5 Western blotting detection image of H5 HA-Ferritin-CO-M6 expression product in silkworm expression system; A is the silkworm expression product of H5 HA-Ferritin-CO-M6; B is the negative control.

[0063] Figure 6 After preliminary purification, H9 HA-Ferritin-CO-M6 or H5 HA-Ferritin-CO-M6 nanoparticle silkworm hemolymph samples were examined by transmission electron microscopy (TEM). The scale bar size was 20 nm. A large number of spherical substances of the expected size could be observed in the image, indicating that the fusion protein successfully self-assembled into nanoparticle antigens. Detailed Implementation

[0064] The present invention will be further described below with reference to specific embodiments, and the advantages and features of the present invention will become clearer with the description. However, these embodiments are merely exemplary and do not constitute any limitation on the scope of the present invention. Those skilled in the art should understand that modifications or substitutions can be made to the details and form of the technical solutions of the present invention without departing from the spirit and scope of the present invention, but all such modifications or substitutions fall within the protection scope of the present invention.

[0065] 1. Experimental materials and reagents

[0066] (1) Strains, viruses and vectors: prokaryotic expression vector pET-28a(+), Escherichia coli TOP10 strain, transfer vector pVL1393, prokaryotic expression strain BL21(DE3), silkworm cells BmN, Sf-9 cells, Hi5 insect cells, silkworm nucleopolyhedrovirus parent strain BmBacmid, alfalfa beet armyworm polyhedrovirus parent strain AcBacmid, and silkworm variety JY1 were all preserved by the Molecular Microbiology Laboratory of the Institute of Biotechnology, Chinese Academy of Agricultural Sciences;

[0067] (2) Ferritin sequence and influenza virus HA protein gene sequence: The common sequence obtained by analysis was sent to GenScript for synthesis and cloned into the prokaryotic expression vector pUC57.

[0068] (3) Enzymes and reagents: Restriction endonucleases, T4 DNA ligase and corresponding buffers were purchased from Promega; LA Taq polymerase and buffers were purchased from TaKaRa; molecular weight standards for DNA and proteins of various specifications were products of TranGen Biotech; 2K Plus II DNA Marker was purchased from Beijing TransGen Biotechnology Co., Ltd.; horseradish peroxidase-labeled goat anti-rabbit IgG secondary antibody was purchased from MBL; DEPC and M-MLV-Rtase (reverse transcriptase) were purchased from Promega.

[0069] (4) Biochemical reagents: Tris, Ampicillin, Kanamycin, IPTG, SDS, urea, imidazole, Triton X-100, TEMED (N,N,N',N'-Tetramethylethylene diamine), Ammonium Persulfate, and Kanamycin were purchased from Sigma-Aldrich; bisacrylamide, acrylamide, IPTG, and X-Gal were purchased from Promega; agarose was a product of Sunbiotech; yeast extract and tryptone were purchased from OXOID (UK); 0.2µm and 0.45µm filters were purchased from Gelman Sciences; ethidium bromide (EB) and Coomassie Brilliant Blue R-250 were purchased from Fluka; Ni-NTA agarose, Proteinase K, and fetal bovine serum were purchased from Invitrogen; bovine serum albumin was purchased from Roche; and all other reagents were domestically produced or imported analytical grade reagents. Primer synthesis and gene sequencing were both completed by Beijing Qingke Xinyue Biotechnology Co., Ltd.

[0070] (5) Culture media: E. coli culture medium was LB medium; silkworm insect cell culture medium was TC-100 purchased from AppliChem.

[0071] (6) Animal experiments of the nano-vaccine constructed by fusing influenza virus with ferritin were conducted in an isolation laboratory.

[0072] 2. Fusion PCR method used for site-directed mutagenesis in the experimental methods.

[0073] The procedure was performed in accordance with the method described by Kuang Feiting et al. (A Novel Method for Vector Construction: Recombinant Fusion PCR, Genomics and Applied Biology, 2012, Vol. 31, No. 6, pp. 634-639).

[0074] Example 1: Preparation and potency assay of H9 HA-Ferritin and H5 HA-Ferritin original sequence nanoparticle vaccines 1. Preparation of related solutions and culture media

[0075] For instructions on preparing solutions and culture media, please refer to relevant reference books (Joseph et al., Molecular Cloning: A Laboratory Manual, 3rd Edition, 2002; Osber et al., A Concise Guide to Molecular Biology, 1998).

[0076] Synthesis of 2H9, H5 hemagglutinin protein gene sequences and ferritin gene sequences.

[0077] To improve the fusion expression of influenza virus hemagglutinin and ferritin, the amino acid sequences of H9 (SEQ ID NO.3) and H5 (SEQ ID NO.4) influenza virus hemagglutinin proteins were analyzed using SignalP and TMHMM software, respectively. The results showed that the signal peptide of H9 hemagglutinin protein consists of the first 18 amino acids, and its extracellular domain consists of the first 524 amino acids. For H5 hemagglutinin protein, the signal peptide consists of the first 16 amino acids, and its extracellular domain consists of the first 532 amino acids.

[0078] To improve the expression efficiency of influenza virus-ferritin fusion nanoparticles and enhance soluble expression, the asparagine (N) at position 19 of the Helicobacter pylori ferritin amino acid sequence (SEQ ID NO.1) was mutated to glutamine (Q) to eliminate the glycosylation site. The influenza virus hemagglutinin protein sequence and the ferritin sequence are linked by a linker peptide (SGG). The first four amino acids of the ferritin amino acid sequence were removed, and then the linker peptide was attached to the fifth amino acid at the N-terminus of the ferritin.

[0079] To improve the translation initiation efficiency of the target gene in the silkworm baculovirus eukaryotic expression system, a Kozak sequence (AAC) was added before the gene. To improve translation termination efficiency, the stop codon was changed to TAA. Furthermore, restriction enzyme sites such as BamHI and EcoRI within the gene sequence were removed, and BamHI was added upstream of the gene, while EcoRI restriction enzyme sites were added downstream, facilitating subsequent cloning into the eukaryotic transfer vector pVL1393.

[0080] The signal peptide of the target gene sequence was removed, and translation was initiated using ATG on the pET-28a(+) vector. In addition, restriction enzyme sites such as BamHI and EcoRI inside the gene sequence were removed, BamHI was added upstream of the gene, and EcoRI restriction enzyme sites were added downstream of the gene to facilitate subsequent cloning into the prokaryotic vector pET-28a(+).

[0081] The designed influenza virus hemagglutinin gene sequence and ferritin sequence were sent to a relevant biotechnology company for synthesis.

[0082] 3. Plasmid construction of influenza virus and ferritin fusion protein

[0083] 3.1 PCR amplification of influenza virus and ferritin fusion protein

[0084] Influenza virus and ferritin were fused together using fusion PCR technology. Specific experimental methods are described in Experiment 2 above. 3.1.1 PCR amplification of E. coli expression plasmids

[0085] PCR amplification of the H9 HA extracellular domain sequence: using plasmid pUC57-H9 HA as a template

[0086] F1 5'-CGGGATCCACTATACTACTAGTAGTAACAG-3' R1 5'-TTGATGATGTCGCCACCGGAGATTTTGTAAGTTCCTTCAG-3'

[0087] PCR amplification of the Ferritin sequence: using pUC57-Ferritin as a template,

[0088] F2 5'-CTGAAGGAACTTACAAAATCTCCGTGGCGACATCATCAA-3' R2 5'-GAATTCTTAGCTCTTGCCGGACTTGG-3'

[0089] Using PCR products H9 HA and Ferritin as templates, overlap-PCR amplified H9 HA-Ferritin.

[0090] F1 5'-CGGGATCCATAACTATACTACTAGTAGTAA-3' R2 5'-GAATTCTTAGCTCTTGCCGGACTTGG-3'

[0091] PCR amplification of the H5 HA extracellular domain sequence: using plasmid pUC57-H5 HA-Ferritin as a template,

[0092] F3 5'-CGGGATCCGATCAGATTTGCATTGGTTAC-3' R3 5'-TTGATGATGTCGCCACCGGATATTTGGTAAGTTCCTATTG-3'

[0093] PCR amplification of the Ferritin sequence: using pUC57-Ferritin as a template,

[0094] F4 5'-CAATAGGAACTTACCAAATATCCGGTGGCGACATCATCAA-3' R4 5'-GAATTCTTAGCTCTTGCCGGACTTGG-3'

[0095] Using PCR products H5 HA and Ferritin as templates, overlap-PCR amplified H5 HA-Ferritin.

[0096] F3 5'-CGGGATCCTTCTTCTTGCAATAGTCAGT-3' R4 5'-GAATTCTTAGCTCTTGCCGGACTTGG-3'

[0097] 3.1.2 PCR amplification of expression plasmids in the silkworm expression system

[0098] PCR amplification of the H9 HA extracellular domain sequence: using plasmid pUC57-H9 HA as a template

[0099] F5 5'-CGGGATCCAACATGGAGACAGCATCACTGATAACT-3' R5 5'-TTGATGATGTCGCCACCGGAGATTTTGTAAGTTCCTTCAG-3'

[0100] PCR amplification of the Ferritin sequence: using pUC57-Ferritin as a template,

[0101]

[0102]

[0103] Using PCR products H9 HA and Ferritin as templates, overlap-PCR amplified H9 HA-Ferritin.

[0104] F5 5'-CGGGATCCAACATGGAGACAGCATCACTGATAACT-3' R6 5'-GAATTCTTAGCTCTTGCCGGACTTGG-3'

[0105] PCR amplification of the H5 HA extracellular domain sequence: using plasmid pUC57-H5 HA-Ferritin as a template,

[0106] F7 5'-CGGGATCCAACATGGAGAAAATAGTGCTTCT-3' R7 5'-TTGATGATGTCGCCACCGGATATTTGGTAAGTTCCTATTG-3'

[0107] PCR amplification of the Ferritin sequence: using pUC57-Ferritin as a template,

[0108] F8 5'-CAATAGGTTACCAAATATCCGGGTGGCGACATCATCAA-3' R8 5'-GAATTCTTAGCTCTTGCCGGACTTGG-3'

[0109] Using PCR products H5 HA and Ferritin as templates, overlap-PCR amplified H5 HA-Ferritin.

[0110] F7 5'-CGGGATCCAACATGGAGAAAATAGTGCTTCT-3' R8 5'-GAATTCTTAGCTCTTGCCGGACTTGG-3'

[0111] The PCR reaction system is shown in Table 1:

[0112] Table 1 PCR reaction system

[0113]

[0114] PCR parameter settings:

[0115]

[0116] 3.2 Purification and Recovery of DNA Fragments Using Glass Milk

[0117] Prepare a 1% (w / v) agarose gel for electrophoresis of the PCR amplification products. Place the agarose gel under UV light, quickly cut off the gel containing a single target nucleic acid band, place it in a 1.5 mL centrifuge tube, weigh it, add three volumes of 6M NaI, and incubate at 37°C to thaw. Add 8 μL of Glassmilk to the completely thawed solution, mix well, incubate on ice for 5 min, shaking twice during the incubation. Centrifuge at 8000 rpm for 10 s and discard the supernatant. Add 800 μL of New Wash, gently tap the tube, and centrifuge again, repeating twice. Discard the supernatant and incubate the centrifuge tube at 37°C for 2–3 min to dry. After drying, add 20 μL of 0.1×TE to dissolve the DNA, mix thoroughly, centrifuge at 12000 rpm for 5 min, and use the supernatant immediately for ligation. Store the remainder at -20°C.

[0118] 3.3 Enzyme digestion treatment of target gene PCR products

[0119] The PCR products were run on a gel, and the correctly recovered products were double-digested with restriction endonucleases BamHI and EcoRI to obtain the target fragments H9 HA-Ferritin and H5 HA-Ferritin. The digestion system is shown in Table 2 below:

[0120] Table 2 Enzyme digestion system

[0121]

[0122] 3.4 Small-scale preparation of competent cells

[0123] Prepare Escherichia coli Top10 competent cells and store at -80℃.

[0124] 3.5 Ligation and transformation of the target gene with pET-28a(+) and pVL1393 vectors

[0125] 3.5.1 Enzyme digestion treatment of pET-28a(+) and pVL1393 vectors

[0126] The transfer vectors pVL1393 and pET-28a(+) were double-digested with restriction endonucleases BamHI and EcoRI, inactivated at 65℃ for 20 min, and stored at -20℃ for later use.

[0127] 3.5.2 Connection

[0128] The target fragment recovered from enzyme digestion was ligated into the transfer vectors pVL1393 and pET-28a(+) after double digestion with BamHI / EcoRI. Ligation was performed overnight at 16°C using T4 DNA ligase. The ligation system is shown in Table 3 below:

[0129] Table 3 Connection System

[0130]

[0131] 3.5.3 Transformation

[0132] Take competent cells stored at -80℃, thaw half of them quickly, add 3μL of the above ligation product, and place on ice for half an hour; place in a 42℃ constant temperature water bath for 90 seconds, then quickly place on ice for 3-5 minutes; add an appropriate amount of 1mL LB medium to the tube, and incubate statically in a 37℃ constant temperature incubator for 60 minutes; centrifuge, discard most of the supernatant, and keep 200μL to spread on LB plates (100μg / mL Amp), incubate upright in a 37℃ constant temperature incubator for 30 minutes, and then invert and incubate overnight.

[0133] 3.6 Rapid Nucleic Acid Extraction Method for Preliminary Screening of Positive Clones

[0134] Single colonies were picked from LB agar plates and inoculated into LB liquid medium (100 μg / mL Amp). The plates were then incubated overnight in a 37°C shaker at 220 rpm. 500 μL of the bacterial culture was collected in a centrifuge tube. 30 μL of loading buffer and 20 μL of phenol / chloroform (1:1) were added, and the mixture was thoroughly vortexed to resuspend the bacterial cells. The cells were centrifuged at 12000 rpm for 3 min, and 8 μL of the supernatant was collected for agarose gel electrophoresis. An empty vector treated in the same manner was used as a control. The bands were observed under UV light using a gel imaging system. Plasmids were extracted from bacterial cultures where the plasmid band was significantly faded.

[0135] 3.7 Extraction of plasmid DNA using SDS alkaline lysis method

[0136] Collect 3 mL of bacterial culture into a centrifuge tube, extract plasmid DNA using the SDS alkaline lysis method, and store at -20℃ for later use.

[0137] 3.8 Identification of positive clones by restriction enzyme digestion and sequencing

[0138] The enzyme digestion system is shown in Table 4 below:

[0139] Table 4 Enzyme digestion system

[0140]

[0141] After reacting at 37℃ for 2 hours, 7 μL was taken and electrophoresed with 1% agarose gel. The plasmid DNA that was correctly digested was sent to Beijing Qingke Xinyue Biotechnology Co., Ltd. for sequencing. The results were consistent with the target gene, and the recombinant plasmids were named pET28a-H9 HA-Ferritin, pET28a-H5 HA-Ferritin, pVL1393-H9 HA-Ferritin, and pVL1393-H5 HA-Ferritin.

[0142] 4 Expression and purification of recombinant plasmids

[0143] 4.1 Induction of recombinant plasmid expression in Escherichia coli

[0144] The correctly identified recombinant expression plasmids pET28a-H9 HA-Ferritin and pET28a-H5 HA-Ferritin were transformed into BL21 competent cells. After induction at 37℃ and a final IPTG concentration of 0.5 mM for 1 h, 2 h, 3 h, 4 h, and 5 h, bacterial cultures were collected, and expression was analyzed by SDS-PAGE electrophoresis. A specific band appeared at approximately 81 kDa for pET28a-H9 HA-Ferritin and at approximately 84 kDa for pET28a-H5 HA-Ferritin, consistent with the expected size of the His-bearing recombinant protein. The uninduced recombinant expression vector did not produce this specific band, indicating successful expression of the fusion protein in *E. coli*. Expression levels gradually increased from 1 to 4 h after IPTG addition, with almost the same amount of recombinant protein accumulated at 5 h and 4 h of induction. The bacterial cells were broken up by ultrasound. A small amount of the target protein was found in the supernatant and the target band was obvious in the precipitate, indicating that the recombinant proteins His-H9 HA-Ferritin and His-H5 HA-Ferritin mainly exist in the form of insoluble inclusion bodies.

[0145] 4.2 High-level expression of recombinant proteins and processing of inclusion body protein samples

[0146] Streak the bacterial strain with high expression levels stored at -80℃, incubate overnight at 37℃, pick a single colony and inoculate it into 4 mL of LB liquid medium (50 μg / mL Kan), incubate overnight at 37℃; transfer 1% of the bacterial culture to 200 mL of LB liquid medium (50 μg / mL Kan), incubate with shaking at 37℃ until the OD value reaches about 0.6, add IPTG (final concentration 0.5 mM), and continue incubation at 37℃ for 4 h; collect the bacterial cells by centrifugation at 5000 rpm for 10 min at 4℃, wash twice with sterile ddH2O, and collect the bacterial cells by centrifugation. Resuspend the bacterial cells in lysis buffer at a rate of 100 μL lysis buffer / mL bacterial culture, incubate on ice for 30 min, and then sonicate on ice to disrupt the lysed cells. Centrifuge at 12,000 rpm for 10 min at 4 °C, discard the supernatant, and the precipitate is the recombinant protein inclusion bodies. Resuspend the precipitate in appropriate amounts of inclusion body washing buffer I and inclusion body washing buffer II and wash, discarding the supernatant. Resuspend the precipitate in an appropriate amount of urea NTA-O buffer and incubate overnight at 4 °C to dissolve.

[0147] 4.3 Nickel column affinity chromatography for purification of recombinant proteins

[0148] The inclusion body solution dissolved overnight was centrifuged at 12,000 rpm for 15 min at 4 °C. The supernatant was collected and filtered through a 0.45 μm membrane. The expressed protein was purified using a Ni-NTA resin chromatography column. Eluent was collected at five gradients: urea NTA-25, urea NTA-50, urea NTA-100, urea NTA-250, and urea NTA-500. One NTA volume was collected from each tube for percolation and eluent collection. SDS-PAGE analysis was used to determine protein binding and the distribution of the target protein in the eluent. Protein electrophoresis showed that the highest protein elution was observed at 50 mM imidazole concentration, with some protein elution at 100 mM concentration, but very little elution at 250 mM concentration. After SDS-PAGE electrophoresis, the purified recombinant protein showed correctly sized, single-band protein.

[0149] 5. Expression and purification of recombinant plasmids in the silkworm eukaryotic expression system

[0150] 5.1 Propagation of the silkworm nucleopolyhedrovirus parent strain BmBacmid and preparation of viral DNA

[0151] Prepare 1×TC-100 medium according to the AppliChem product instructions, adjust the pH to 6.22 with 2M NaOH, filter and sterilize the medium, add 10% fetal bovine serum, and culture silkworm cells BmN at 27°C. Infect approximately 50 mL of logarithmic growth phase cells with the parent strain of silkworm nucleopolyhedrovirus. After 3–4 days, collect the viral infection fluid, centrifuge at 10,000 rpm for 10 min, remove the precipitate, and centrifuge the supernatant at 25,000 rpm for 1 hour. Remove the supernatant again, and resuspend the viral particles in 1 mL of viral DNA extraction buffer (1 L contains 12.1 g Tris, 33.6 g EDTA, 14.1 g KCl, pH 7.5). Transfer the precipitate to a 1.5 mL centrifuge tube, add proteinase K to a final concentration of 50 μg / mL, and incubate at 50 °C for 2 hours. Then add 35% Sarkorsel to a final concentration of 1%, and continue incubating at 50 °C for 2 hours. Extract the cells sequentially with equal volumes of saturated phenol, phenol:chloroform (1:1), and chloroform. Transfer the upper aqueous phase to a new tube and add 1 / 10 volume of 3M phenol solution. Add NaCl, then add 2 volumes of anhydrous ethanol, incubate at -20°C for at least 2 hours to precipitate viral DNA, centrifuge at 5000 rpm for 10 minutes, wash the precipitate once with 75% ethanol, and freeze-dry. Dissolve in 100 μl TE buffer and store at 4°C for later use.

[0152] 5.2 Recombinant silkworm baculovirus rBmBacmid (P PH -H9 HA-Ferritin, P PH Construction and acquisition of -H5 HA-Ferritin

[0153] Approximately 1×10 6 Cells at 15cm 2 After cells adhere to the culture flask, remove the culture medium containing fetal bovine serum (FBS), wash three times with FBS-free medium, and add 1.5 ml of FBS-free medium. Add 1 μg of silkworm baculovirus parental strain BmBcmid DNA (patent number: ZL201110142492.4), 2 μg of recombinant transfer plasmid pVL1393-H9HA-Ferritin or pVL1393-H5HA-Ferritin, and 5 μl of liposomes to a sterile tube. Make up the volume to 60 μl with sterile double-distilled water, mix gently, and let stand for 15 min. Then, add the mixture dropwise to the culture flask for co-transfection. After incubation at 27°C for 4 h, add 1.5 ml of serum-free medium and 300 μl of FBS. Incubate at 27°C for 4–5 days, and collect the supernatant for recombinant virus rBmBacmid (P... PH -H9 HA-Ferritin, P PHScreening for -H5 HA-Ferritin. Inoculate an appropriate amount of cells (approximately 70-80%) into 35mm petri dishes. After cell adhesion, aspirate the culture medium. Dilute the co-transfection supernatant to different concentrations, and add 1ml of the co-transfection solution to the adherent cells, distributing it evenly. Infect at 27℃ for 1 hour, then aspirate the infection solution. Melt 2% low-melting-point agarose gel in a 60℃ water bath, cool to 40℃, and mix thoroughly with 4ml of preheated 2×TC-100 medium (containing 20% ​​FBS). Add 4ml of gel to each petri dish, and after solidification, seal with Parafilm. Incubate upside down at 27℃ for 3-5 days, observing under a microscope. Select plaques without polyhedromes, repeat the above steps, and after 2-3 rounds of purification, obtain pure recombinant silkworm baculovirus rBmBacmid (P PH -H9 HA-Ferritin, P PH -H5 HA-Ferritin).

[0154] 5.3 Recombinant virus rBmBacmid (P PH -H9 HA-Ferritin, P PH Amplification of -H5 HA-Ferritin in silkworm cells

[0155] Recombinant silkworm baculovirus rBmBacmid(P) PH -H9 HA-Ferritin, P PH Normally growing BmN cells were infected with α-H5 HA-Ferritin and cultured for 3 days. The supernatant was then collected, which contained a large amount of recombinant virus rBmBacmid (P-H5 HA-Ferritin). PH -H9 HA-Ferritin, P PH -H5 HA-Ferritin).

[0156] 5.4 Identification of Recombinant Viruses

[0157] The integration of exogenous genes was analyzed using PCR. The extraction method for cell-free viral genomic DNA was as follows: 150 μl of viral supernatant was taken, 150 μl (0.5 mol / L) of NaOH was added and mixed well, then 20 μl (8 mol / L) of ammonium acetate was added and mixed well. The DNA was then extracted once with equal volumes of phenol and chloroform, respectively. After ethanol precipitation, the DNA was dissolved in 20 μl of TE buffer.

[0158] One μl of the viral genomic DNA was amplified by PCR under the following conditions: denaturation at 94℃ for 5 min, 94℃ for 1 min, 58℃ for 1 min, and 72℃ for 3 min, for 30 cycles, followed by a final extension at 72℃ for 10 min. One 15 μl of the reaction product was analyzed by electrophoresis, confirming the successful acquisition of the recombinant virus.

[0159] 5.5H9 HA-Ferritin and H5 HA-Ferritin expression in silkworm bodies and pupae

[0160] The silkworm pupae used were of the high-expression variety JY1 (preserved in our laboratory). JY1 silkworm rearing was conducted according to the standard methods described in *Chinese Sericulture* (Shanghai Science and Technology Press, 1991), edited by Lü Hongsheng. Forty-eight hours after feeding, silkworms of similar average weight and 15 pupae of similar average weight seven days after cocooning were selected. Each pupae and silkworm was inoculated with approximately 1.0 × 10⁻⁶ gram. 5 pfurBmBacmid(P PH -H9 HA-Ferritin, P PH -H5 HA-Ferritin), after 4-5 days, diseased silkworm pupae and silkworm blood were collected and frozen at -20℃ for detection by double antibody sandwich ELISA.

[0161] 5.6 Collection and purification of H9 HA-Ferritin and H5 HA-Ferritin virus-like particles

[0162] Silkworm pupae expressing the target gene were homogenized in pre-cooled PBS (1:9 ratio) in a homogenizer and then filtered through a 0.45 μm filter. The homogenate was then added to a 30% sucrose solution at a concentration of 1.5 × 10⁻⁶. 5 Centrifuge at ultra-high speed for 2 hours. Redissolve the precipitate to its original volume with a solution containing 0.1 M NaCl and Tris-HCl (pH 7.0), elute with 0.5 M NaCl and Tris-HCl (pH 7.0) using cation exchange chromatography packing material SP (GE), and then pass through molecular sieve chromatography S200 (GE). Purity can reach 95%, and yield can reach over 40%. This study also demonstrated that the target protein expressed in silkworms can self-assemble into virus-like particles at high concentrations, and established a corresponding purification method for the genetically engineered chicken infectious bursal disease virus virus-like particle antigen expressed in silkworms. 6. Western blotting detection.

[0163] Recombinant virus-infected silkworm hemolymph was diluted 10-fold with PBS (pH 7.4) and sonicated. SDS-PAGE gel electrophoresis was then performed, with a stacking gel concentration of 5% and a separating gel concentration of 15%. Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane using a semi-dry transfer method. The membrane was blocked with 3% BSA prepared with PBST. Primary antibodies (1:1000 dilution) were used to detect His-Ferritin expressed in prokaryotes and the serum of mice immunized with His-Ferritin protein. Secondary antibodies (1:5000 dilution) were used. Finally, DAB (diaminobenzidine) was used for color development, followed by termination with deionized water. Western blotting results showed that specific bands of 81 kDa (H9HA-Ferritin) and 84 kDa (H5HA-Ferritin) were detected in the supernatant of the silkworm hemolymph samples after recombinant virus infection.

[0164] 7. Blood coagulation test

[0165] 7.1 Material Preparation

[0166] 96-well V-type microplate, micropipette (with dropper); Alsevers solution, chicken red blood cell suspension (1%); PBS pH 7.2.

[0167] 7.2 Operating Procedures

[0168] Add 0.025 mL of PBS to wells 1-12 of the microplate and change the dropper. Add 0.025 mL of virus suspension to well 1 and mix. Add 0.025 mL of virus solution from well 1 to well 2, mix, and then add 0.025 mL to well 3. Continue this 2-fold serial dilution up to well 11. Discard 0.025 mL from well 11 and change the dropper. Add 0.025 mL of PBS to each well. Include a red blood cell control well without any sample. Add 0.025 mL of 1% chicken red blood cell suspension to each well (shake the chicken red blood cell suspension thoroughly before adding). Shake to mix and incubate at room temperature for 20-40 minutes before observing the results. Red blood cells in the control wells will settle to the bottom of the well in a distinct button-like shape.

[0169] Table 5. ELISA titers of H9 HA-Ferritin and H5 HA-Ferritin original sequence expression products.

[0170] Group valence H9 HA-Ferritin 1:1024 H5 HA-Ferritin 1:800

[0171] ELISA result interpretation: A positive result was defined as a P / N ratio (OD value of positive well minus OD value of blank control well / OD value of negative well) greater than or equal to 2.1. The results showed that the ELISA titers of H9 HA-Ferritin and H5 HA-Ferritin gene expression products could reach 1:1024 and 1:800, respectively.

[0172] Table 6. Hemagglutination titers of H9 HA-Ferritin and H5 HA-Ferritin original sequence expression products

[0173] Group valence H9 HA-Ferritin 1:2048 H5 HA-Ferritin 1:1600

[0174] Tables 5 and 6 present the experimental data for the expression products of the original H9 HA-Ferritin and H5 HA-Ferritin gene sequences. Example 2: Preparation and efficacy testing of nanoparticle vaccines after designing and optimizing concordant sequences based on the original H9 HA-Ferritin and H5 HA-Ferritin sequences.

[0175] 1. Preparation of solutions and culture media

[0176] For specific methods of preparing the solution and culture medium, please refer to Example 1.

[0177] 2. Gene acquisition of conserved sequence of influenza virus hemagglutinin protein

[0178] This invention compares the original amino acid sequence of the influenza virus hemagglutinin protein from Example 1 with 20 other hemagglutinin amino acid sequences obtained from NCBI to obtain a similar sequence. This similar sequence is then optimized and further processed using OptimumGene. TM The technology optimizes the amino acid sequences of H5 and H9 hemagglutinin proteins. The optimized amino acid sequences of the hemagglutinin protein and the ferritin monomer subunit amino acid sequences are then modified according to the codon preference of the silkworm. Optimization is performed on various parameters affecting gene transcription efficiency, translation efficiency, and protein folding, including GC content, CpG dinucleotide content, codon preference, mRNA secondary structure, mRNA free energy stability, RNA instability gene sequences, and repetitive sequences, while maintaining the final translated protein sequence unchanged. These are named H9 HA-Ferritin-CO (SEQ ID NO.11) and H5 HA-Ferritin-CO (SEQ ID NO.13). The specific optimization process is detailed in Example 1.

[0179] 3. Plasmid construction of fusion protein

[0180] For specific experimental methods, please refer to Example 1.

[0181] H9 HA-Ferritin-CO fusion PCR primers:

[0182] H9 HA hemagglutinin extracellular domain PCR primers:

[0183] F9:CGGGATCCAACATGGAAGTAGTAAGTCTGATAACC

[0184] R9:TTGATGATGTCGCCACCGGAAATCTTGTATGTACCCTCGCTTTC

[0185] Ferritin PCR primers:

[0186] F10: GAAAGCGAGGGTACATACAAGATTTCCGGTGGCGACATCATCAA

[0187] R10: GAATTCTTAGCTCTTGCGGGACTTGG

[0188] Overlap PCR primers:

[0189] F9: CGGGATCCAACATGGAAGTAGTAAGTCTGATAACC

[0190] R10: GAATTCTTAGCTCTTGCGGGACTTGG

[0191] H5 HA-Ferritin-CO fusion PCR primers:

[0192] H5 HA hemagglutinin extracellular domain PCR primers:

[0193] F11:CGGGATCCAACATGGAAAAAATCGTGCTGCTG

[0194] R11:GGTATTTACCAGATCCTGTCCATTTCCGGTGGCGACATCATCAAGCTG

[0195] Ferritin PCR primers:

[0196] F12: CAGCTTGATGATGTCGCCACCGGAAATGGACAGGATCTTGGTAAATACC

[0197] R12: CGGAATTCTTAGCTCTTGCGGGACTTGGCGAT

[0198] Overlap PCR primers:

[0199] F11: CGGGATCCAACATGGAAAAAATCGTGCTGCTG

[0200] R12: CGGAATTCTTAGCTCTTGCGGGACTTGGCGAT

[0201] 3.1 Ligation and transformation of the target gene with the pVL1393 vector

[0202] 3.2 Rapid nucleic acid extraction method for preliminary screening of positive clones

[0203] For specific experimental methods, please refer to Example 1.

[0204] 3.3 Extraction of plasmid DNA using SDS alkaline lysis method

[0205] For specific experimental methods, please refer to Example 1.

[0206] 3.4 Identification of positive clones by restriction enzyme digestion and sequencing

[0207] For specific experimental methods, please refer to Example 1.

[0208] 4. Expression and purification of recombinant plasmids pVL1393-H9 HA-Ferritin-CO and pVL1393-H5 HA-Ferritin-CO in the silkworm expression system.

[0209] 4.1 Propagation of the silkworm nucleopolyhedrovirus parent strain BmBacmid and preparation of viral DNA

[0210] For specific experimental methods, please refer to Example 1.

[0211] 4.2 Construction and Obtaining Recombinant Silkworm Baculovirus rBmBacmid

[0212] For specific experimental methods, please refer to Example 1.

[0213] 4.3 Amplification of recombinant virus rBmBacmid in silkworm cells

[0214] For specific experimental methods, please refer to Example 1.

[0215] 4.4 Identification of Recombinant Viruses

[0216] For specific experimental methods, please refer to Example 1.

[0217] 4.5H9 HA-Ferritin-CO and H5 HA-Ferritin-CO expression in silkworm bodies and pupae

[0218] For specific experimental methods, please refer to Example 1.

[0219] 4.6 Collection and purification of H9 HA-Ferritin-CO and H5 HA-Ferritin-CO virus-like particles

[0220] For specific experimental methods, please refer to Example 1.

[0221] 5. Western blotting detection

[0222] For specific experimental methods, please refer to Example 1.

[0223] 6. Blood coagulation test

[0224] For specific experimental methods, please refer to Example 1.

[0225] 7. Result Evaluation

[0226] Table 7 ELISA titers of H9 HA-Ferritin-CO and H5 HA-Ferritin-CO gene expression products

[0227] Group valence H9 HA-Ferritin 1:1024 H5 HA-Ferritin 1:800 H9 HA-Ferritin-CO 1:1600 H5 HA-Ferritin-CO 1:1600

[0228] ELISA result interpretation: A positive result was defined as a P / N ratio (OD value of positive well minus OD value of blank control well / OD value of negative well) greater than or equal to 2.1. The results showed that the ELISA titer of H9 HA-Ferritin-CO and H5 HA-Ferritin-CO gene expression products could reach 1:1600.

[0229] Table 8. Hemagglutination titers of H9 HA-Ferritin-CO and H5 HA-Ferritin-CO gene expression products

[0230] Group valence H9 HA-Ferritin 1:2048 H5 HA-Ferritin 1:1600 H9 HA-Ferritin-CO 1:3200 H5 HA-Ferritin-CO 1:3200

[0231] The results in Tables 7 and 8 show that the expression level of the codon-optimized sympathetic sequence has been greatly improved, indicating that the modification and optimization work in this embodiment is successful.

[0232] Example 3: Preparation and efficacy testing of nanoparticle vaccines based on amino acid point mutations of H9 HA-Ferritin-CO and H5 HA-Ferritin-CO mutants.

[0233] 1 Experimental Methods

[0234] 1.1 Construction of H9 HA-Ferritin-CO and H5 HA-Ferritin-CO amino acid sequence single-point mutant genes Based on the results of Example 2, the present invention obtained H9 HA-Ferritin-C and H5 HA-Ferritin-C mutants. Using the gene sequences of H9 HA-Ferritin-C and H5 HA-Ferritin-C mutants with optimized codons as templates, multiple primer pairs were designed to perform site-directed mutagenesis on conserved sequences. Site-directed mutagenesis was performed using the fusion PCR method, the method of which is described in Example 1.

[0235] The mutation sites are H9: N40S, N41D, A47T, L51I, M58I, G63N, P83L, P101S, T138K, E181G, N191H, H192Q, D196E, T197A, G236R, I267V, Q304H, D367N, N419S, V469M; H5: V40I, K51R, T52A, K56R, S72R, N100S, H126R, G155E, E186K, D187N, V190I, L191M, G193W, I242M, N289Y, N325S, Y366F, E406G, D462E or Q501H. The resulting mutants were named H9 HA-Ferritin-COM (N40S, N41D, A47T, L51I, M58I, G63N, P83L, P101S, T138K, E181G, N191H, H192Q, D196E, T197A, G236R, I267V, Q304H, D367N, N419S, V469M), H5 HA-Ferritin-COM(V40I, K51R, T52A, K56R, S72R, N100S, H126R, G155E, E186K, D 187N, V190I, L191M, G193W, I242M, N289Y, N325S, Y366F, E406G, D462E, Q501H).

[0236] Primers required for single point mutation of amino acids using H9 HA-Ferritin-CO and H5 HA-Ferritin-CO:

[0237] H9 HA-Ferritin-CO:

[0238] (1) Upstream and downstream primers on both sides:

[0239] F: CGGGATCCAACATGGAAGTAGTAAGTCTGATAACC

[0240] R: CGGAATTCTTAGCTCTTGCGGGACTTGGCG

[0241] (2) Forward and reverse primers for the middle upstream and downstream: 1.

[0243] F: GGACACGCTGACAGAG AGT AATGTGCCGGTTAC

[0244] R: GTAACCGGCACATT ACT CTCTGTCAGCGTGTCC 2.

[0246] F: CTGACAGAGAAC GAT GTGCCGGTTACTCACGC

[0247] R: GCGTGAGTAACCGGCAC ATC GTTCTCTGTCAG 3.

[0249] F: CCGGTTACTCAC ACC AAAGAACTGTTGCACACC

[0250] R: GGTGTGCAACAGTTCTTT GGT GTGAGTAACCGG 4. <000,0646>F: AAAGAACTG ATA CACACCGAGCATAACGGTATGC

[0253] R: GCATACCGTTATGCTCGGTGTG TAT CAGTTCTTT 5.

[0255] F: CGAGCATAACGGT ATA CTCTGCGCCACTGGTTTAG

[0256] R: CTAAACCAGTGGCGCAGAG TAT ACCGTTATGCTCG 6.

[0258] F: CTCTGCGCCACT AAT TTAGGACATCCTCTTATCCTG

[0259] R:CAGGATAAGAGGATGTCCTAA TTA AGTGGCGCAGAG 7.

[0261] F:GTTTAATTTACGGAAAC TTG TCCTGTGATCTCTTAC

[0262] R:GTAAGAGATCACAGGA CAA GTTTCCGTAAATTAAAC 8.

[0264] F:CATTGTGGAGAGG AGT TCTGCTGTTAATGGAC

[0265] R:GTCCATTAACAGCAGA ACT CCTCTCCACAATG 9.

[0267] F:CAAATCTTCCCTGAC AAG ATATGGAACGTAAC

[0268] R:GTTACGTTCCATAT CTT GTCAGGGAAGATTTG 10.

[0270] F:CCAACAATCAG GGT AAGAACATCCTTTTTATG

[0271] R:CATAAAAAGGATGTTCTT ACC CTGATTGTTCC 11.

[0273] F:GTGGGGAATT CAC CACCCTCCAACGGACACAG

[0274] R:CTGTGTCCGTTGGAGGGTG GTG AATTCCCCAC 12.

[0276] F:CTTTTTATGTGGGGAATTAAT CAA CCTCCAACGG

[0277] R:CCGTTGGAGG TTG ATTAATTCCCCACATAAAAAG 13.

[0279] F:CACCCTCCAACG GAA ACAGTCCAAACTAATCTGTAC

[0280] R:GTACAGATTAGTTTGGACTGT TTC CGTTGGAGGGTG 14.

[0282] F:CACCCTCCAACGGAC GCT GTCCAAACTAATCTG

[0283] R:CAGATTAGTTTGGAC AGC GTCCGTTGGAGGGTG 15.

[0285] F:GGTGAATGGTCTCCAA CGC AGAATTGACTAC

[0286] R:GTAGTCAATTCT GCG TTGGAGACCATTCACC 16.

[0288] F:CCTGGTACGGCCAC GTA CTTTCGGGCGAAAGTC

[0289] R:GACTTTCGCCCGAAAG TAC GTGGCCGTACCAGG 17.

[0291] F:GACATTGCCGTTC CAC AATGTATCCAAATACG

[0292] R:CGTATTTGGATACATT GTG GAACGGCAATGTC 18.

[0294] F:CAACACTCTAAC AAT CAGGGCGTTGGTATG

[0295] R:CATACCAACGCCCTG ATT GTTAGAGTGTTG 19.

[0297] F:GACTGAACATGATC AGT AACAAAATCGAC

[0298] R:GTCGATTTTGTT ACT GATCATGTTCAGTC 20.

[0300] F: GATCGAACGCG ATG GAAGACGGAAAAGG

[0301] R:CCTTTTCCGTCTTC CAT CGCGTTCGATC

[0302] H5 HA-Ferritin-CO:

[0303] (1) Upstream and downstream primers on both sides:

[0304] F: CGGGATCCAACATGGAAAAAATCGTGCTGCTGTTCGC

[0305] R: CGGAATTCTTAGCTCTTGCGGGACTTGGCG

[0306] (2) Intermediate upstream and downstream primers: 1.

[0308] F:CCATTATGGAGAAGAAC ATT ACTGTGACCCACGC

[0309] R:GCGTGGGTCACAGT AAT GTTCTTCTCCATAATGG 2.

[0311] F: GGACATCCTGGAG CGC ACACATAACGGCAAG

[0312] R:CTTGCCGTTATGT GTG CGCTCCAGGATGTCC 3.

[0314] F: GGACATCCTGGAGAAA GCT CATAACGGCAAGC

[0315] R:GCTTGCCGTTATG AGC TTTCTCCAGGATGTCC 4.

[0317] F:GAAAACACATAACGGC CGC CTGTGCGATC

[0318] R:GATCGCACAG GCG GCCGTTATGTGTTTTC 5.

[0320] F:GATCCTGAAGGACTGC CGC GTGGCAGGC

[0321] R:GCCTGCCAC GCG GCAGTCCTTCAGGATC 6.

[0323] F:GTGGAGAAAGCC AGT CCTGCTAATGATCTGTGC

[0324] R:GCACAGATCATTAGCAGG ACT GGCTTTCTCCAC 7.

[0326] F:GTCCAGAATCAAC CGC TTCGAAAAGATCC

[0327] R:GGATCTTTTCGAA GCG GTTGATTCTGGAC 8.

[0329] F:CGCTTGTCCATACCAG GAA AACAGCTCCTTC

[0330] R:GAAGGAGCTGTTTTCCTGGTATGGACAAGCG 9.

[0332] F:CAACACCAACCAG AAA GATCTGCTGGTG

[0333] R:CACCAGCAGATC TTT CTGGTTGGTGTTG 10.

[0335] F:CAACACCAACCAGGAG AAC CTGCTGGTGCTGTG

[0336] R:CACAGCACCAGCAG GTTCTCCTGGTTGGTGTTG 11.

[0338] F:GGAGGATCTGCTG ATT CTGTGGGGAATC

[0339] R:GATTCCCCACAG AAT CAGCAGATCCTCC 12.

[0341] F:GAGGATCTGCTGGTG ATG TGGGGAATCCACC

[0342] R:GGTGGATTCCCCA CAT CACCAGCAGATCCTC 13.

[0344] F:GGTGCTGTGG TGG ATCCACCATCCAAACG

[0345] R:CGTTTGGATGGTGGAT CCA CCACAGCACC 14.

[0347] F:CCAGTCTGGACGG ATG GATTTCTTTTGG

[0348] R:CCAAAAGAAATCCATCCGTCCAGACTGG 15.

[0350] F:GGTGGAATACGGG TAC TGCAATACCCGCTGTC

[0351] R:GACAGCGGGTATTGCA GTA CCCGTATTCCACC 16.

[0353] F:GTGAAAAGC AGT AAGCTGGTGCTGGCTAC

[0354] R:GTAGCCAGCACCAGCTT ACT GCTTTTCAC 17.

[0356] F:GTGGATGGGTGGGTACGGT TTC CACCATAGTAAC

[0357] R: GTTACTATGGTG GAA ACCGTACCACCCATCCAC 18.

[0359] F: GAACACCCAGTTC GGT GCTGTGGGGAGG

[0360] R:CCTCCCCACAGC ACC GAACTGGGTGTTC 19.

[0362] F: GAAAAATCTGTAT GAA AAAGTGAGGCTCC

[0363] R: GGAGCCTCACTTT TTC ATACAGATTTTTC 20.

[0365] F: GGCACTTACGAC CAC CCTCAGTATTCAGAGGR: CCTCTGAATACTGAGG GTG GTCGTAAGTGCC

[0366] Plasmid construction of 2H9 HA-Ferritin-COM and H5 HA-Ferritin-COM mutants

[0367] For specific experimental methods, please refer to Example 1.

[0368] 3. Transformation and Identification of Recombinant Plasmids

[0369] For specific experimental methods, please refer to Example 1.

[0370] 4. Expression and purification of recombinant plasmids in silkworm expression system

[0371] 4.1 Propagation of the silkworm nucleopolyhedrovirus parent strain BmBacmid and preparation of viral DNA

[0372] The specific method is the same as in Example 1.

[0373] 4.2 Construction and Obtaining Recombinant Silkworm Baculovirus

[0374] The specific method is the same as in Example 1.

[0375] 4.3 Amplification of recombinant virus rBmBacmid in silkworm cells

[0376] For specific experimental methods, please refer to Example 1.

[0377] 4.4 Identification of Recombinant Viruses

[0378] For specific experimental methods, please refer to Example 1.

[0379] The specific methods for expressing the H9 HA-Ferritin-COM and H5 HA-Ferritin-COM mutant genes in silkworm bodies and pupae are the same as in Example 1.

[0380] 4.6 Collection and purification of H9 HA-Ferritin-COM and H5 HA-Ferritin-COM virus-like particles

[0381] The specific method is the same as in Example 1.

[0382] 5. Western blotting detection

[0383] For specific experimental methods, please refer to Example 1.

[0384] 6. Blood coagulation test

[0385] For specific experimental methods, please refer to Example 1.

[0386] 7. Result Evaluation

[0387] Table 9. ELISA titers of expression products of H9 HA-Ferritin-COM and H5 HA-Ferritin-CM mutants.

[0388]

[0389]

[0390] ELISA result interpretation criteria: A positive result is defined as a P / N ratio (OD value of positive well minus OD value of blank control well / OD value of negative well) greater than or equal to 2.1. Although the highest ELISA value is around 3200, this experiment uses threshold and dilution factor as quantitative indicators, and the specific sample volume will vary depending on the P / N value. Similarly, because it is also a two-fold dilution, the time at which the hemagglutination phenomenon can be determined varies, and although the hemagglutination value is the same, it does not mean that the content is completely consistent. Similar phenomena exist in later experiments, but will not be explained in detail.

[0391] Table 10 Hemagglutination titers of H9 HA-Ferritin-COM and H5 HA-Ferritin-COM mutant expression products

[0392]

[0393]

[0394] As can be seen from the data in Tables 9 and 10, the expression levels of the products of six single mutants (N40S, N41D, A47T, N191H, H192Q, and D196E) obtained by making point mutations of amino acids based on the same sequence (SEQ ID NO.11) were significantly improved compared with the expression level of the same sequence.

[0395] As can be seen from the data in Tables 9 and 10, the expression levels of the products of six single mutants (V40I, K51R, K56R, V190I, L191M, G193W) obtained by making point mutations of amino acids based on the same sequence (SEQ ID NO.13) were significantly improved compared with the expression level of the same sequence.

[0396] Example 4: Preparation and efficacy testing of nanoparticle vaccines with two-site amino acid mutations using H9 HA-Ferritin-COM and H5 HA-Ferritin-COM.

[0397] Based on the results of Example 3, it was determined that mutations at certain sites were effective mutations that could increase the expression levels of the H9HA-Ferritin-COM and H5HA-Ferritin-COM mutants. Considering that the amino acid sequence is the primary structure of a protein and determines its higher-order structure, and that some of the single-site mutations in the amino acids performed in Example 3 may have interrelated positions, a two-site mutation of amino acids was attempted. This invention combines single mutation sites that can increase expression levels, such as H9 HA (N40S, N41D, A47T, N191H, H192Q, or D196E) and H5 HA (V40I, K51R, K56R, V190I, L191M, or G193W), into pairs for two-site mutation. The two-site mutation is based on the single-site mutation sequence obtained in Example 3, using (H9 HA-Ferritin-COM, H5 HA-Ferritin-COM) as templates and corresponding primers to perform a second-site mutation through fusion PCR, thereby obtaining the target fragment with two-site mutations. The fusion PCR method is described in Example 1.

[0398] The double mutation site for H9 HA has 15 combinations: N40S-N41D, N40S-A47T, N40S-N191T, N40S-H192Q, N40S-D196E, N41D-A47T, N41D-N191H, N41D-H192Q, N41D-D196E, A47T-N191H, A47T-H192Q, A47T-D196E, N191H-H192Q, N191H-D196E, or H192Q-D196E. The resulting mutant is named H. 9HA-Ferritin-COD (N40S-N41D, N40S-A47T, N40S-N191T, N40S-H192Q, N40S-D196E, N41D-A47T, N41D-N191H, N 41D-H192Q, N41D-D196E, A47T-N191H, A47T-H192Q, A47T-D196E, N191H-H192Q, N191H-D196E or H192Q-D196E), H5 HA-Ferritin-COD mutants (V40I-K51R, V40I-K56R, V40I-V190I, V40I-L191M, V40I-G193W, K51R-K56R, K51R-V190I, K51R-L191M, K51R-G193W, K56R-V190I, K56R-L191M, K56R-G193W, V190I-L191M, V190I-G193W or L191M-G193W).

[0399] The H9 HA-Ferritin-CO and H5 HA-Ferritin-CO partial amino acid double-site mutations are due to the close proximity of the mutation sites.

[0400] To avoid repetitive mutations, additional primers are required as follows:

[0401] H9 HA-Ferritin-COD:

[0402] N40S-N41D:

[0403] F: GGACACGCTGACAGAG AGTGAT GTGCCGGTTAC

[0404] R: GTAACCGGCAC ATCACT CTCTGTCAGCGTGTCC

[0405] N191-H192Q

[0406] F: GTGGGGAATT CACCAACCTCCAACGGACACAG

[0407] R:CTGTGTCCGTTGGAGG TTGGTG AATTCCCCAC

[0408] H192Q-D196E

[0409] F:GAATTAAT CAA CCTCCAACG GAA ACAGTCCAAACTAATCTG

[0410] R:CAGATTAGTTTGGACTGT TTC CGTTGGAGG TTG ATTAATTC

[0411] H5 HA-Ferritin-C-O-D:

[0412] K51R-K56R:

[0413] F:GGACATCCTGGAG CGC ACACATAACGGC CGC CTGTGCGATCTG

[0414] R:CAGATCGCACAG GCG GCCGTTATGTGT GCG CTCCAGGATGTCC

[0415] V190I-L191M:

[0416] F:CAACCAGGAGGATCTGCTG ATTATG TGGGGAATCCACCATCC

[0417] R:GGATGGTGGATTCCCCA CATAAT CAGCAGATCCTCCTGGTTG

[0418] V190I-G193W:

[0419] F:CAGGAGGATCTGCTG ATT CTGTGG TGG ATCCACCATCCAAAC

[0420] R:GTTTGGATGGTGGAT CCA CCACAG AAT CAGCAGATCCTCCTG

[0421] L191M-G193W:

[0422] F: GAGGATCTGCTGGTG ATG TGG TGG ATCCACCATCC

[0423] R: GGATGGTGGAT CCA CCA CAT CACCAGCAGATCCTC

[0424] 1. Preparation of solutions and culture media

[0425] The preparation methods for the solutions and culture media are the same as in Example 1.

[0426] Plasmid construction of 2H9 HA-Ferritin-COD and H5 HA-Ferritin-COD mutants

[0427] For specific experimental methods, please refer to Example 1.

[0428] 3. Transformation and Identification of Recombinant Plasmids

[0429] For specific experimental methods, please refer to Example 1.

[0430] 4. Expression and purification of recombinant plasmids pVL1393-H9 HA-Ferritin-COD and pVL1393-H5 HA-Ferritin-COD in the silkworm expression system.

[0431] 4.1 Propagation of the silkworm nucleopolyhedrovirus parent strain BmBacmid and preparation of viral DNA

[0432] The specific method is the same as in Example 1.

[0433] 4.2 Construction and Obtaining Recombinant Silkworm Baculovirus rBmBacmid

[0434] The specific method is the same as in Example 1.

[0435] After 2-3 rounds of purification, pure recombinant silkworm baculovirus rBmBacmid (P) was obtained. PH -H9 HA-Ferritin-COD, P PH -H5 HA-Ferritin-COD).

[0436] 4.3 Recombinant virus rBmBacmid (P PH -H9 HA-Ferritin-COD, P PH Amplification of -H5 HA-Ferritin-COD in silkworm cells

[0437] Recombinant silkworm baculovirus rBmBacmid(P) PH -H9 HA-Ferritin-COD, P PH Normally growing BmN cells were infected with β-H5HA-Ferritin-COD and cultured for 3 days. The supernatant was then collected, which contained a large amount of recombinant virus rBmBacmid (P-H5HA-Ferritin-COD). PH -H9 HA-Ferritin-COD, P PH -H5 HA-Ferritin-COD).

[0438] 4.4 Identification of Recombinant Viruses

[0439] The specific method is the same as in Example 1.

[0440] 4.5H9 HA-Ferritin-COD and H5 HA-Ferritin-COD expression in silkworm bodies and pupae

[0441] The specific method is the same as in Example 1.

[0442] 4.6 Collection and purification of H9 HA-Ferritin-COD and H5 HA-Ferritin-COD virus-like particles

[0443] The specific method is the same as in Example 1.

[0444] 5. Western blotting detection

[0445] The specific experimental method is the same as in Example 1.

[0446] 6. Blood coagulation test

[0447] The specific experimental method is the same as in Example 1.

[0448] 7. Result Evaluation

[0449] Table 11 ELISA titers of H9 HA-Ferritin-COD and H5 HA-Ferritin-COD mutant expression products

[0450]

[0451]

[0452] Table 12 Hemagglutination titers of H9 HA-Ferritin-COD and H5 HA-Ferritin-COD mutant expression products

[0453]

[0454]

[0455] The data in Tables 11 and 12 show that, among the amino acid double-site mutations of the same sequence, the expression levels of three double mutants (N40S-N41D, N41D-A47T, and A47T-H192Q) obtained by double-site mutation of amino acids based on the same sequence (SEQ ID NO. 11) were significantly increased compared with the expression level of the same sequence.

[0456] As can be seen from the data in Tables 11 and 12, the expression levels of three double mutants (V40I-K51R, K51R-V190I, or V190I-G193W) obtained by double-site mutation of amino acids based on the same sequence (SEQ ID NO.13) were significantly improved compared with the expression level of the same sequence.

[0457] Example 5: Preparation and efficacy testing of nanoparticle vaccines with multiple amino acid mutations using H9 HA-Ferritin-COD and H5 HA-Ferritin-COD.

[0458] Based on the results of Example 4, considering that the amino acid sequence is the primary structure of a protein and determines its higher-order structure, it is speculated that the single-point mutations of amino acids may have resulted in some mutation sites being close to each other and related. Therefore, multi-site mutations of amino acids were attempted. This invention, through analysis of glycosylation sites, determined that six single-mutation sites could effectively increase the expression level of the target gene. Therefore, multi-site mutation is based on the two-site mutation sequences obtained in Example 4. Using these sequences (H9 HA-Ferritin-COD, H5 HA-Ferritin-COD) as templates and appropriate primers, multi-site mutations were performed using fusion PCR to obtain the target fragment with multiple mutations. The fusion PCR method is described in Example 1.

[0459] To avoid duplicate mutations at multiple sites during PCR, two additional pairs of primers were used:

[0460] H9 HA-Ferritin-CO-M6 D196E:

[0461] F: TCACCACCCTCCAACG GAA ACAGTCCAAACTAATC

[0462] R: GATTAGTTTGGACTGT TTC CGTTGGAGGGTGGTGA

[0463] H5 HA-Ferritin-CO-M6 G193W:

[0464] F: GATCTGCTGATTATGTGG TGG ATCCACCATCCAAAC

[0465] R:GTTTGGATGGTGGAT CCA CCACATAATCAGCAGATC

[0466] The following two combinations were obtained: H9 HA (N40S-N41D-A47T-N191H-H192Q-D196E); H5HA (V40I-K51R-K56R-V190I-L191M-G193W). These were named H9HA-Ferritin-CO-M6 (N40S-N41D-A47T-N191H-H192Q-D196E) and H5HA-Ferritin-CO-M6 (V40I-K51R-K56R-V190I-L191M-G193W).

[0467] H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 were expressed in the silkworm eukaryotic expression system and the AcMNPV-insect cell expression system.

[0468] Plasmid construction of 1H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 mutants

[0469] For specific experimental methods, please refer to Example 1.

[0470] 2. Transformation and Identification of Recombinant Plasmids

[0471] The specific method is the same as in Example 1.

[0472] 3. Expression and purification of recombinant plasmids in silkworm expression system and AcMNPV-insect cell expression system

[0473] 3.1 Reproduction of the parent virus strain and preparation of viral DNA

[0474] 3.1.1 Propagation of the silkworm nucleopolyhedrovirus parent strain BmBacmid and preparation of viral DNA

[0475] The specific method is the same as in Example 1.

[0476] 3.1.2 Construction and preparation of AcBacmid DNA

[0477] Prepared according to the following method (Zhang Zhifang, Li Yinv, Yi Yongzhu, et al. Insect bioreactors expressing multiple exogenous genes and their construction methods and applications [P]. China: CN102286534A, 2011.):

[0478] The recombinant viral DNA containing the target gene was prepared according to the following method: 1×TC-100 medium was prepared according to the product instructions of AppliChem, the pH was adjusted to 6.22 with 2M NaOH, the medium was filtered and sterilized, 10% fetal bovine serum was added, and Sf-9 cells were cultured at 27°C. Infect logarithmically growing cells with approximately 5 mL of recombinant AcBacmid virus containing the target gene. After 3–4 days, collect the viral infection solution, centrifuge at 10,000 rpm for 10 min, remove the precipitate, and centrifuge the supernatant at 25,000 rpm for 1 hour. Remove the supernatant, and resuspend the viral particles in 1 mL of viral DNA extraction buffer (1 L contains 12.1 g Tris, 33.6 g EDTA, 14.1 g KCl, pH 7.5). Transfer the precipitate to a 1.5 mL centrifuge tube, add proteinase K to a final concentration of 50 μg / mL, and incubate at 50 °C for 2 hours. Then add 35% Sarkorsel to a final concentration of 1%, and continue incubating at 50 °C for 2 hours. Extract sequentially with equal volumes of saturated phenol, phenol:chloroform (1:1), and chloroform. Transfer the upper aqueous phase to a new tube, and add 1 / 10 volume of 3M phenol extract. Add NaCl, then add 2 volumes of anhydrous ethanol, incubate at -20°C for at least 2 hours to precipitate viral DNA, centrifuge at 5000 rpm for 10 minutes, wash the precipitate once with 75% ethanol, and freeze-dry. Dissolve in 100 μl TE buffer and store at 4°C for later use.

[0479] 3.2 Construction and Obtaining Recombinant Baculovirus

[0480] 3.2.1 Construction and Obtaining Recombinant Silkworm Baculovirus rBmBacmid

[0481] The specific method is the same as in Example 1.

[0482] 3.2.2 Construction and Obtaining Recombinant Baculovirus rAcBacmid

[0483] The dose is approximately 0.5–1 × 10⁻⁶. 6 Sf-9 cells at 15cm 2In a culture flask, cells were incubated overnight in an adherent state. The FBS-containing medium was removed, and the cells were washed three times with serum-free medium, followed by 1.5 ml of serum-free medium. In a sterile tube, 1 μg of AcBcmid DNA, 2 μg of recombinant transfer plasmid pVL1393-H9 HA-Ferritin or pVL1393-H5 HA-Ferritin, and 5 μl of liposomes were added sequentially. The volume was brought to 60 μl with sterile double-distilled water, gently mixed, and allowed to stand for 15 min. The mixture was then added dropwise to the culture flask for co-transfection. After incubation at 27°C for 4 h, 1.5 ml of serum-free medium and 300 μl of FBS were added. The cells were incubated at 27°C for 4–5 days, and the supernatant was collected for screening of the recombinant virus rAcBacmid. Seed an appropriate amount of Sf-9 cells (approximately 70-80%) into 35 mm petri dishes. After cell adhesion, aspirate the culture medium. Dilute the co-transfection supernatant to different concentrations, and add 1 ml of the co-transfection solution to the adherent cells, distributing it evenly. Infect at 27°C for 1 hour, then aspirate the infection solution. Melt 2% low-melting-point agarose gel in a 60°C water bath, cool to 40°C, and mix thoroughly with 2×TC-100 medium (containing 20% ​​FBS) preheated to 40°C. Add 4 ml of gel to each petri dish, and after solidification, seal with Parafilm. Incubate upside down at 27°C for 3-5 days, observing under a microscope. Select plaques without polyhedromes, repeat the above steps, and after 2-3 rounds of purification, obtain pure recombinant baculoviruses rAcBacmid-H9 HA-Ferritin-CO-M6 and rAcBacmid-H5 HA-Ferritin-CO-M6.

[0484] 3.3 Recombinant virus amplification in cells

[0485] 3.3.1 Amplification of recombinant virus rBmBacmid in silkworm cells

[0486] The specific method is the same as in Example 1.

[0487] 3.3.2 Amplification of recombinant virus rAcBacmid in insect Sf-9 cells

[0488] Normally growing Sf-9 cells were infected with the above-mentioned recombinant silkworm baculoviruses rAcBacmid-H9 HA-Ferritin-CO-M6 and rAcBacmid-H5HA-Ferritin-CO-M6. After culturing for 96 hours, the infected cells were collected, and the supernatant contained a large number of recombinant viruses rAcBacmid-H9 HA-Ferritin-CO-M6 and rAcBacmid-H5HA-Ferritin-CO-M6.

[0489] 3.4 Identification of recombinant virus rBmBacmid

[0490] The specific method is the same as in Example 1.

[0491] 3.5 Expression of the target gene in silkworms and silkworm pupae

[0492] The specific method is the same as in Example 1.

[0493] 3.6 Identification and expression of recombinant virus rAcBacmid in insect Hi5- cells

[0494] PCR was used to analyze the integration of exogenous genes. Viral genomic DNA was extracted.

[0495] PCR amplification was performed on 1 μl of the viral genomic DNA, and electrophoresis analysis was performed on 15 μl of the reaction product. The results showed that recombinant viruses rAcBacmid-H9 HA-Ferritin-CO-M6 and rAcBacmid-H5 HA-Ferritin-CO-M6 were obtained.

[0496] The culture media of the above recombinant viruses rAcBacmid-H9 HA-Ferritin-CO-M6 and rAcBacmid-H5 HA-Ferritin-CO-M6 were cultured at a ratio of 10... 6-7 100 mL of Hi5 cells were infected with Pfu, and the infected cells were collected after 96 hours and frozen at -20°C for ELISA detection.

[0497] 3.7 Collection and purification of virus-like particles, the target gene expression product

[0498] The specific method is the same as in Example 1.

[0499] 4. Result Evaluation

[0500] Table 13 ELISA detection of expression products of H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 mutants in silkworm and AcMNPV-insect cell expression systems.

[0501] Group valence H9 HA-Ferritin-COD 1:6400 H5 HA-Ferritin-COD 1:6400 H9 HA-Ferritin-CO-M6 (Silkworm) 1:12800 H5 HA-Ferritin-CO-M6 (Silkworm) 1:12800 AcH9 HA-Ferritin-CO-M6 (AcMNPV-Insect Cell) 1:1280 AcH5 HA-Ferritin-CO-M6 (AcMNPV-Insect Cell) 1:1280

[0502] ELISA result interpretation: A positive result is defined as a P / N ratio (OD value of positive well minus OD value of blank control well / OD value of negative well) greater than or equal to 2.1; the results show that the ELISA titer of H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 gene expression products can reach 1:12800.

[0503] The ELISA values ​​for the expression products of H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 mutants in the AcMNPV-insect cell expression system represent the expression level per milliliter of insect cells. The hemagglutination titer is calculated similarly.

[0504] Table 14 Hemagglutination detection of expression products of H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 mutants in silkworm and AcMNPV-insect cell expression systems.

[0505] Group valence H9 HA-Ferritin-COD 1:12800 H5 HA-Ferritin-COD 1:12800 H9 HA-Ferritin-CO-M6 (Silkworm) 1:51200 H5 HA-Ferritin-CO-M6 (Silkworm) 1:32768 AcH9 HA-Ferritin-CO-M6 (AcMNPV-Insect Cell) 1:5120 AcH5 HA-Ferritin-CO-M6 (AcMNPV-Insect Cell) 1:2560

[0506] The data in Tables 13 and 14 show that the expression level of the mutant obtained by performing multiple amino acid site mutations on the fusion protein homologous sequence was significantly improved compared with the expression levels of the single mutant and double mutant mentioned above.

[0507] 5. Western Blotting Detection

[0508] The specific method is the same as in Example 1. Western blotting results showed that specific bands of 81 kDa (H9 HA-Ferritin) and 84 kDa (H5 HA-Ferritin) could be detected in the supernatant of silkworm hemolymph samples infected with recombinant virus (see Example 1). Figure 4 and Figure 5 ).

[0509] 6. Electron Microscopy Observation

[0510] Use a 1ml syringe to draw a certain amount of 1% uranium acetate and set aside. Use another syringe to draw a certain amount of distilled water. After preliminary purification of H9HA-Ferritin-CO-M6 or H5HA-Ferritin-CO-M6 nanoparticles of silkworm hemolymph, dilute with the suspension. Drop the suspended sample onto the sealing film to form a small droplet. Hold the grid with the tip of tweezers, with the film side down, and pick up the sample. Then blot dry with filter paper, and wash away excess suspension. Wash 5 times. After drying, place the grid on the droplet of 1% uranium acetate staining solution and stain for 3 minutes. Blot away excess stain from the edge of the copper grid with filter paper. Repeat 2-3 times. After drying, examine under a microscope. The results are as follows. Figure 6 As shown, nanoparticles of the expected size are visible, with cage-like structures having a diameter of about 12 nanometers. Upon closer inspection, antenna-like protrusions can be seen.

[0511] Example 6: Construction and animal experiments of recombinant viruses for mammalian expression of pVLCAG-H9 HA-Ferritin-CO-M6 and pVLCAG-H5 HA-Ferritin-CO-M6 baculoviruses.

[0512] 1. Construction of pVLCAG vector

[0513] The upstream of the polyclonal restriction site of the pVL1393 vector is a polyhedral gene promoter (Pph). Upstream of this promoter is an EcoR V restriction site, and downstream of the polyclonal restriction site, the first restriction site is BamHI. Using these two restriction sites, Pph is cleaved and ligated into the CAG promoter, which is derived from the pCAGGS vector. The SV40-polyA terminator is derived from the pEGFP-N3 vector. PCR primers for both upstream and downstream of the CAG promoter were designed: CAG-1F as the upstream primer with a HincII restriction site, and CAG-1R as the downstream primer with an EcoR I restriction site. Using the pCAGGS vector as a template, the CAG promoter was amplified and ligated into the pMD18T vector. After sequencing verification, the promoter was recovered by double digestion with HincII and EcoR I. Since HincII digestion produces blunt ends, the recovered CAG promoter was ligated to a vector recovered from EcoR V and BamHI digestion. After screening on Amp-resistant LB plates, enzyme digestion identification, and final sequencing confirmation, the pVL1393 vector ligated with the CAG promoter was obtained. The SV40 terminator, compatible with the CAG promoter, was then inserted using the NotI and BglII restriction sites in the multiple cloning site.

[0514] PCR primers for the SV40 terminator were designed, with SV10-1F as the upstream primer, containing NotI and PstI restriction sites, and SV10-1R as the downstream primer, containing a BglII restriction site. The SV40 terminator was amplified using the pEGFP vector as a template and ligated into pMD18T. After sequencing verification, a fragment of approximately 250 bp was recovered by NotI and BglII digestion. This fragment was then ligated into the pVL1393 vector, which had been treated with NotI and BglII and contained a CAG promoter. After verification, the pVLCAG vector was obtained. This vector is used to transfer the exogenous gene, along with the upstream and downstream CAG promoters and the SV40 terminator, to the baculovirus polyhedrosis gene site during co-transfection, constructing a recombinant baculovirus transfer vector for presenting exogenous genes into vertebrate cells or individuals.

[0515] 2. Construction of recombinant viruses for presenting reporter genes

[0516] 2.1 The H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 genes were cloned into a gene presentation transfer vector.

[0517] The H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 gene fragments with restriction sites from Example 4 were digested and recovered, and ligated into the pVLCAG vector with the same restriction site. After verification, pVLCAG-H9HA-Ferritin-CO-M6 and pVLCAG-H5 HA-Ferritin-CO-M6 were obtained.

[0518] 2.2 Construction and large-scale production of recombinant viruses for gene presentation

[0519] BmN cells were co-transfected with reBmBac using pVLCAG-H9 HA-Ferritin-CO-M6 and pVLCAG-H5 HA-Ferritin-CO-M6 transfer vectors to obtain recombinant viruses Bm-CAG H9 HA-Ferritin-CO-M6 and Bm-CAG H5 HA-Ferritin-CO-M6, respectively. During co-transfection, pVL1393-Luc was still used as a control to determine the success of co-transfection. The virus purification process was the same as above.

[0520] Fifth-instar silkworm larvae were infected with recombinant virus, and the hemolymph was harvested 4-5 days later, containing a large amount of amplified recombinant virus.

[0521] The silkworm hemolymph was diluted with PBS and sonicated (10 s × 10 times), then centrifuged at 12000 rpm for 10 minutes to remove cell debris, and then centrifuged at 15 × 10⁻⁶ ppm. 4 Centrifuge for 3 hours, remove supernatant, and resuspend the precipitate in an appropriate amount of PBS to obtain preliminarily purified recombinant baculovirus particles. Generally, 10 mL of recombinant virus from silkworm blood is centrifuged and then resuspended in 2 mL of PBS. The amount of recombinant virus after resuspension is approximately 2.5 × 10⁻⁶. 12 PFU / ML (approximately 5 × 10) 12 Viral genomes (vg) / mL, viral copy number, were calculated using quantitative real-time PCR with primers GJ-1F (CGAACGGAGACGATGGATGTGG) and GJ-1R (GTGCCGAGCGATTGTAAGGGATC) based on the BmNPV viral DNA backbone sequence.

[0522] 3. Recombinant virus expression in mammalian cells

[0523] Vero cells were used as the target for gene delivery, and 100 MOI of each of the recombinant viruses Bm-CAG H9 HA-Ferritin-C-O-M6 and Bm-CAG H5 HA-Ferritin-C-O-M6 were used for the study. The method steps are as follows:

[0524] 1) Vero cells (1×10 6 cell / well) were seeded in a six-well plate and cultured adherently at 3℃ for 8 - 12 h

[0525] 2) 1×10 8 PFU of purified recombinant viruses Bm-CAG H9 HA-Ferritin-C-O-M6 and Bm-CAG H5 HA-Ferritin-C-O-M6 were added to the cells in the six-well plate and incubated at 37℃ for 1 h

[0526] 3) After incubation, the medium containing the virus was removed, and normal DMEM medium containing serum was replaced. The cells were treated for about 42 h, and the expression products were collected. The hemagglutination titer was detected to be 1:800.

[0527] 4 Animal experiments

[0528] 4.1 Inject the expression products of H9 HA-Ferritin-C-O-M6 and H5 HA-Ferritin-C-O-M6 into animals

[0529] The silkworm pupae obtained by expressing the optimal sequences H9 HA-Ferritin-C-O-M6 and H5 HA-Ferritin-C-O-M6 analyzed in the eukaryotic expression system of Bombyx mori were injected into animals at a dose of 2 9-10 HA units / feather to prepare vaccines with 250 feather portions / g and 160 feather portions / g of silkworm pupae. [[ID=2,6]]

[0530] The preparation method is as follows: Weigh 10 g of silkworm pupae expressing the nanoparticle antigens H9 HA-Ferritin-C-O-M6 and H5 HA-Ferritin-C-O-M6 respectively, add 90 ml of PBS buffer, and stir with a stirrer for 5 - 10 min to mix well. The mother liquor is prepared and placed in a sterilized bottle. The 206 adjuvant is sterilized in advance and placed in an incubator at 30℃ for heat preservation. The mother liquor is first placed on ice. When mixing with the adjuvant, first add 3 ml of the adjuvant to a 15 ml centrifuge tube, slowly drip 3 ml of the mother liquor, and homogenize with a homogenizer for 3 min. Add ciprofloxacin hydrochloride, and the dosage is 30 - 50 mg / 1 kg of chicken body weight. The vaccine is milky white. When detecting the quality of the vaccine, a small amount can be taken out and centrifuged at 3000 rpm for 15 min. If the vaccine does not separate layers, it is qualified. Healthy silkworm pupae are treated in the same way to prepare a vaccine as a control.[[ID=2,8]] [[ID=2,9]]

[0531] The optimal sequences H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 obtained from the analysis were expressed in the AcBacmid-insect cell eukaryotic expression system. The resulting cell pellets were then processed according to a 2-step process. 9-10 HA units per bird are injected into the animals.

[0532] Preparation method: The antigen expressed by insect cells is subjected to ultrasonic disruption of the cell precipitate according to the amount of hemagglutination units required for vaccine preparation, and then mixed with the appropriate adjuvant.

[0533] The procedure was performed according to the methods described in the Veterinary Pharmacopoeia of the People's Republic of China (2010 edition, China Agriculture Press). Seventy 21-day-old SPF chickens were used, with ten chickens from each family receiving a subcutaneous injection (0.2 ml) of a vaccine prepared from the expression products of H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 in the AcMNPV-insect cell expression system, injected subcutaneously into the neck and back of each of the other ten chickens. Ten chickens were inoculated with a vaccine prepared from healthy silkworm pupae as a negative control group, ten chickens received no immunization as a normal control group, and ten chickens were inoculated with a traditional vaccine strain as a positive control. Twenty-one days after inoculation, approximately 2 ml of blood was collected from the subwing vein, placed in a test tube at an angle, incubated at 37°C for 2 hours, and then transferred to room temperature overnight. Serum was transferred to centrifuge tubes and centrifuged at 2000 rpm for 10 min. Serum was then collected, and HI antibody levels were measured using avian influenza virus (H9 subtype) antigen. The HI titer in both the negative silkworm pupa immunization group and the normal control group should not exceed 1:4. The HI titer of traditional vaccine strains is 1:64-128, while the HI titers of H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 expression samples in the silkworm eukaryotic expression system are above 1:256 and 1:200, respectively. The HI titers of H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 expression samples in the AcMNPV-insect cell expression system are above 1:128 and 1:100, respectively.

[0534] 4.2 Presentation of exogenous genes into mice and chickens using recombinant viruses

[0535] 4.2.1 Presentation of the H9 HA-Ferritin-CO-M6 gene in mice

[0536] Purified recombinant virus Bm-CAG H9 HA-Ferritin-CO-M6 was administered via tail vein injection (1×10⁻⁶).10 vg / animal) and perfusion (1×10 10 The antibody was administered to mice via a dose of vg / mouse, with each mouse weighing approximately 25g. Serum was collected from mice on days 5, 11, 17, and 21 to determine antibody titers.

[0537] 4.2.2 Presentation of the H5 HA-Ferritin-CO-M6 gene in mice

[0538] Purified recombinant virus Bm-CAG H5 HA-Ferritin-CO-M6 was administered via tail vein injection (1×10⁻⁶). 10 vg / animal) and perfusion (1×10 10 The antibody was administered to mice via a dose of vg / mouse, with each mouse weighing approximately 25g. Serum was collected from mice on days 5, 11, 17, and 21 to determine antibody titers.

[0539] 4.2.3 Presentation of the H9 HA-Ferritin-CO-M6 gene into chickens

[0540] Similar to the treatment in mice, the purified recombinant virus Bm-CAG H9 HA-Ferritin-CO-M6 was administered via tail vein injection (3 × 10⁻⁶). 10 vg / feather) and irrigation (6×10 10 Antibody antibodies were administered to 15-day-old chickens at a dose of (vg / bird), with each chicken weighing approximately 150g. Serum was collected on days 5, 11, 17, and 21 to determine antibody titers.

[0541] 4.2.4 Presentation of the H5 HA-Ferritin-CO-M6 chicken serum gene into chickens

[0542] Purified recombinant virus Bm-CAG H5 HA-Ferritin-CO-M6 was administered via tail vein injection (3×10⁻⁶). 10 vg / feather) and irrigation (6×10 10 Antibody antibodies were administered to 15-day-old chickens at a dose of (vg / bird), with each chicken weighing approximately 150g. Serum was collected on days 5, 11, 17, and 21 to determine antibody titers.

[0543] 5. Neutralizing antibody titer

[0544] The specific experimental steps are described above. The neutralizing antibody titer was highest at 21 days. The specific results are shown in Table 15.

[0545] Table 15 Neutralizing antibody titers in mouse and chicken serum of H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 (21 days)

[0546] composition valence Healthy silkworm pupae (control group) (chicken) 1:4 Traditional vaccines (for chickens) 1:512 Healthy silkworm pupae (control) (mice) 1:4 Traditional vaccines (mice) 1:256 H9 HA-Ferritin-CO-M6 mouse serum 1:2048 H5 HA-Ferritin-CO-M6 mouse serum 1:1600 H9 HA-Ferritin-CO-M6 chicken serum 1:3200 H5 HA-Ferritin-CO-M6 chicken serum 1:3200

[0547] As can be seen from the data in Table 15, the antibody titers produced by presenting mutants with multiple amino acid sites of the fusion protein to mice and chickens were higher than those of healthy silkworm pupae and traditional vaccines.

[0548] 6. Blood coagulation inhibition

[0549] For specific steps, please refer to Example 4. The best results are obtained after 21 days, and the results are shown in Table 16.

[0550] Table 16 Hemagglutination inhibition titers of H9 HA-Ferritin-CO-M6 and H5 HA-Ferritin-CO-M6 in mouse and chicken serum

[0551] composition valence Healthy silkworm pupae (control group) (chicken) 1:4 Traditional vaccines (for chickens) 1:128 Healthy silkworm pupae (control) (mice) 1:4 Traditional vaccines (mice) 1:128 H9 HA-Ferritin-CO-M6 mouse serum 1:160 H5 HA-Ferritin-CO-M6 mouse serum 1:160 H9 HA-Ferritin-CO-M6 chicken serum 1:256 H5 HA-Ferritin-CO-M6 chicken serum 1:256

[0552] As can be seen from the data in Table 16, the antibody titers produced by presenting mutants with multiple amino acid sites of the fusion protein to mice and chickens were higher than those of healthy silkworm pupae and traditional vaccines. SEQUENCE LISTING <110> Institute of Biotechnology, Chinese Academy of Agricultural Sciences <120> Self-assembled ferritin nanoparticle antigens, influenza vaccines and their preparation methods <130> BJ-2002-190327A-F <160> 26 <170> PatentIn version 3.5 <210> 1 <211> 166 <212> PRT <213> Helicobacter pylori <400> 1 Met Leu Ser Lys Asp Ile Ile Lys Leu Leu Asn Glu Gln Val Asn Lys 1 5 10 15 Glu Met Asn Ser Ser Asn Leu Tyr Met Ser Met Ser Ser Trp Cys Tyr 20 25 30 Thr His Ser Leu Asp Gly Ala Gly Leu Phe Leu Phe Asp His Ala Ala 35 40 45 Glu Glu Tyr Glu His Ala Lys Lys Leu Ile Ile Phe Leu Asn Glu Asn 50 55 60 Asn Val Pro Val Gln Leu Thr Ser Ile Ser Ala Pro Glu His Lys Phe 65 70 75 80 Glu Gly Leu Thr Gln Ile Phe Gln Lys Ala Tyr Glu His Glu Gln His 85 90 95 Ile Ser Glu Ser Ile Asn Asn Ile Val Asp Ala Ile Lys Ser Lys Asp 100 105 110 His Ala Thr Phe Asn Phe Leu Gln Trp Tyr Val Ala Glu Gln His Glu 115 120 125 Glu Glu Val Leu Phe Lys Asp Ile Leu Asp Lys Ile Glu Leu Ile Gly 130 135 140 Asn Glu Asn His Gly Leu Tyr Leu Ala Asp Gln Tyr Val Lys Gly Ile 145 150 155 160 Ala Lys Ser Arg Lys Ser 165 <210> 2 <211> 510 <212> DNA <213> Helicobacter pylori <400> 2 atgtccggtg gcgacatcat caagctgctg aacgaacagg tgaacaagga gatgcagtcc 60 agcaacctgt acatgtctat gtcttcatgg tgctacaccc actcactgga cggagctggt 120 ctgttcctgt tcgaccacgc tgccgaggaa tacgaacacg ccaagaagct gatcatcttc 180 ctgaacgaga acaacgtgcc tgtccagctg acctccatca gcgctcccga acacaagttc 240 gagggtctga ctcaaatctt ccagaaggcc tacgaacacg agcagcacat ctctgaatca 300 atcaacaaca tcgtggacca cgctatcaag agcaaggacc acgccacttt caacttcctg 360 caatggtacg tggctgagca gcacgaggaa gaggtcctgt tcaaggacat cctggacaag 420 atcgaactga tcggcaacga gaaccacgga ctgtacctgg ctgaccagta cgtcaagggc 480 atcgccaagt cccgcaagag ctaagaattc 510 <210> 3 <211> 560 <212> PRT <213> Influenza virus <400> 3 Met Glu Thr Ala Ser Leu Ile Thr Ile Leu Leu Val Val Thr Gly Ser 1 5 10 15 Ser Ala Asp Lys Ile Cys Ile Gly Tyr Gln Ser Thr Asn Ser Thr Glu 20 25 30 Thr Val Asp Thr Leu Thr Glu Asn Asn Val Pro Val Thr His Ala Lys 35 40 45 Glu Leu Leu His Thr Glu His Asn Gly Met Leu Cys Ala Thr Ser Leu 50 55 60 Gly Gln Pro Leu Ile Leu Asp Thr Cys Thr Ile Glu Gly Leu Ile Tyr 65 70 75 80 Gly Asn Pro Ser Cys Asp Ile Leu Leu Gly Gly Arg Glu Trp Ser Tyr 85 90 95 Ile Val Glu Arg Pro Ser Ala Val Asn Gly Leu Cys Tyr Pro Gly Asn 100 105 110 Val Glu Asn Leu Glu Glu Leu Arg Ser Leu Phe Ser Ser Ala Lys Ser 115 120 125 Tyr Gln Arg Ile Gln Ile Phe Pro Asp Thr Ile Trp Asn Val Ser Tyr 130 135 140 Ser Gly Thr Ser Lys Ala Cys Ser Asp Ser Phe Tyr Arg Ser Met Arg 145 150 155 160 Trp Leu Thr Gln Lys Asn Asn Ala Tyr Pro Ile Gln Asp Ala Gln Tyr 165 170 175 Thr Asn Asn Gln Glu Lys Asn Ile Leu Phe Met Trp Gly Ile Asn His 180 185 190 Pro Pro Thr Asp Thr Ala Gln Thr Asn Leu Tyr Thr Arg Thr Asp Thr 195 200 205 Thr Thr Ser Val Ala Thr Glu Glu Ile Asn Arg Thr Phe Lys Pro Leu 210 215 220 Ile Gly Pro Arg Pro Leu Val Asn Gly Leu Met Gly Arg Ile Asn Tyr 225 230 235 240 Tyr Trp Ser Val Leu Lys Pro Gly Gln Thr Leu Arg Ile Lys Ser Asn 245 250 255 Gly Asn Leu Ile Ala Pro Trp Tyr Gly His Ile Leu Ser Gly Glu Ser 260 265 270 His Gly Arg Ile Leu Lys Thr Asp Leu Lys Arg Gly Ser Cys Thr Val 275 280 285 Gln Cys Gln Thr Glu Lys Gly Gly Leu Asn Thr Thr Leu Pro Phe Gln 290 295 300 Asn Val Ser Lys Tyr Ala Phe Gly Asn Cys Ser Lys Tyr Ile Gly Ile 305 310 315 320 Lys Ser Leu Lys Leu Ala Val Gly Leu Arg Asn Val Pro Ser Arg Ser 325 330 335 Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp 340 345 350 Ser Gly Leu Val Ala Gly Trp Tyr Gly Phe Gln His Ser Asn Asn Gln 355 360 365 Gly Val Gly Met Ala Ala Asp Arg Asp Ser Thr Gln Lys Ala Ile Asp 370 375 380 Lys Ile Thr Ser Lys Val Asn Asn Ile Val Asp Lys Met Asn Lys Gln 385 390 395 400 Tyr Glu Ile Ile Asp His Glu Phe Ser Glu Phe Glu Thr Arg Leu Asn 405 410 415 Met Ile Asn Asn Lys Ile Asp Asp Gln Ile Leu Asp Ile Trp Ala Tyr 420 425 430 Asn Ala Glu Leu Leu Val Leu Leu Glu Asn Gln Lys Thr Leu Asp Glu 435 440 445 His Asp Ala Asn Val Asn Asn Leu Tyr Asn Lys Val Lys Arg Ala Leu 450 455 460 Gly Ser Asn Ala Val Glu Asp Gly Lys Gly Cys Phe Glu Leu Tyr His 465 470 475 480 Lys Cys Asp Asp Gln Cys Met Glu Thr Ile Arg Asn Gly Thr Tyr Asn 485 490 495 Arg Arg Lys Tyr Gln Glu Glu Ser Arg Leu Glu Arg Gln Lys Ile Glu 500 505 510 Gly Val Lys Leu Glu Ser Glu Gly Thr Tyr Lys Ile Leu Thr Ile Tyr 515,520,525 Ser Thr Val Ala Ser Ser Leu Val Ile Ala Met Gly Phe Ala Ala Phe 530 535 540 Leu Phe Trp Ala Met Ser Asn Gly Ser Cys Arg Cys Asn Ile Cys Ile 545 550 555 560 <210> 4 <211> 1742 <212> DNA <213> Influenza Virus <400> 4 agcaaagca ggggaatttc ataccactc aaaatggaga cagcatcact gataactata 60 ctactagtag taacaggag cagtgcagat aagatctgca tcggctatca atcaaac 120 tccacagaaa ctgtagacac actaacagaa aacaatgtcc ctgtgacaca tgccaaagaa 180 ttgctccaca cagagcataa tgggatgctg tgtgcaa gcttgggaca acctttatt 240 ctagacactt gtaccattga aggactaatc tatggcaatc cttcttgtga tatattgttg 300 ggaggaagag aatggtccta tatcgtcgag agaccatcag ctgttaacgg attgtgttat 360 cccgggaatg tagaaatct agaagagcta agtcactct ttagttctgc taagtcttat 420 caaaggatcc agattttccc agacacaatc tggaatgtgt cttatagtgg gacaagcaag 480 gcatgttcgg attcattcta cagaagcatg agatggttga ctcaaaagaa caacgcttac 540 cctattcaag acgcccaata cacaaataat caagaaaaga acattctttt catgtggggc 600 ataaatcacc cacccactga cactgcacag acaaatctgt acacaagaac cgacacaaca 660 acgagtgtgg caacagaaga aataaatagg accttcaaac cattgatagg accaaggcct 720 cttgtcaacg gtttgatggg aagaattaat tattattggt cagtattaaa accgggtcaa 780 acactgcgaa taaaatctaa tggaaatcta atagctccat ggtatggaca cattctttca 840 ggagagagcc acgggagaat cctgaagact gacttaaaaa gaggtagctg cacagtgcaa 900 tgtcagacag agaagggtgg cttaaacaca acattgccat tccaaaatgt gagtaagtat 960 gcatttggaa actgctcaaa atacattggc ataaagagtc tcaaacttgc agttggtctg 1020 aggaatgtac cttctagatc cagtagagga ctattcgggg ccatagcagg attcatagag 1080 ggaggttggt caggactagt tgctggttgg tatgggttcc agcattcaaa taaccaaggg 1140 gttggtatgg cagcagatag ggactcaacc caaaggcaa ttgataaat aacatccaaa gtgaataca tagtagacaa aatgaacaag cagtatgaaa ttatcgatca tgaattcagc gagtttgaa ctagacttaa catgattaac aataagattg acgatcaaat cctggatata tgggcatata atgcagaatt gctagttctg cttgaaaacc agaaaacact cgatgagcat gatgcaaatg taacaaattt gtacaataaa gtgaagaggg cattgggttc caatgcggtg 1500. 1500. 1500. 1500. 1500. 1500. 1500. 1500. 1500. 1500 attcggaacg ggacctacaa cagaaggaag tatcaagagg agtcaagatt agaaagacag aaaatagagg gggtcaagct ggaatctgaa ggaacttaca aaatcctcac catttattcg actgtcgcct catctcttgt aattgcaatg gggtttgctg cctttttgtt ctgggccatg 1680. tccaatgggt cttgcagatg caacatttgt atataattgg caaaaacacc cttgtttcta ct 1742 <210> 5 <211> 568 <212> PRT <213> Influenza virus <400> 5 Met Glu Lys Ile Val Leu Leu Leu Ala Ile Val Ser Leu Val Lys Ser 1 5 10 15 Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val 20 25 30 Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile 35 40 45 Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asp Gly Val Lys 50 55 60 Pro Leu Ile Leu Arg Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80 Pro Met Cys Asp Glu Phe Pro Asn Val Ser Glu Trp Ser Tyr Ile Val 85 90 95 Glu Lys Thr Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn 100 105 110 Asn Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn Arg Phe Glu 115 120 125 Lys Ile Lys Ile Ile Pro Lys Ser Ser Trp Pro Asp His Glu Ala Ser 130 135 140 Leu Gly Val Ser Ser Ala Cys Pro Tyr Gln Gly Gly Pro Ser Phe Tyr 145 150 155 160 Arg Asn Val Val Trp Leu Ile Lys Lys Asn Asn Thr Tyr Pro Thr Ile 165 170 175 Lys Glu Ser Tyr His Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp 180 185 190 Gly Ile His His Pro Asn Asp Glu Glu Glu Gln Thr Arg Ile Tyr Lys 195 200 205 Asn Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220 Leu Val Pro Lys Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly 225 230 235 240 Arg Val Glu Phe Phe Trp Thr Ile Leu Lys Ser Asn Asp Thr Ile Asn 245 250 255 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Asn Ala Tyr Lys Ile 260 265 270 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Leu Glu Tyr Gly 275 280 285 Asn Cys Ser Thr Lys Cys Gln Thr Pro Val Gly Ala Ile Asn Ser Ser 290 295 300 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320 Tyr Val Lys Ser Asn Arg Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335 Pro Gln Gly Glu Gly Arg Arg Lys Lys Arg Gly Leu Phe Gly Ala Ile 340 345 350 Ala Gly Phe Ile Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr 355 360 365 Gly Tyr His His Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Arg 370 375 380 Glu Ser Thr Gln Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser 385 390 395 400 Ile Ile Asp Lys Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe 405 410 415 Asn Asn Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp 420 425 430 Gly Phe Leu Asp Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met 435 440 445 Glu Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu 450 455 460 Tyr Asp Lys Val Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly 465 470 475 480 Asn Gly Cys Phe Glu Phe Tyr His Arg Cys Asp Asn Glu Cys Met Glu 485,490,495 Ser Val Arg Asn Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala 500 505 510 Arg Leu Lys Arg Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly 515,520,525 Thr Tyr Gln Ile Will Be Leu Ile Tyr Will Be Thr Val Ala Will Be Leu Wing 530 535 540 Leu Phe Leu Trp Met Cys Ser Asn Gly 545 550 555 560 Ser Leu Gln Cys Arg Ile Cys Ile 565 <210> 6 <211> 1719 <212> DNA <213> Influenza Virus <400> 6 caatctgtca aaatggagaa atagtgctt cttcttgcaa tagtcagtct tgttaaaagt 60 gatcagattt gcattggtta ccatgcaac aactcacag agcaggttga cacaataatg 120 gaaaagaacg tcactgttac acacgctca gatactgg aaagacaca caacgggaaa 180 ctctgcgatc tagatggagt gaagcctcta attttaagag attgtagtgt agctggatgg 240 ctcctcggga acccaatgtg tgacgaattc cccaatgtgt cggaatggtc ctacatagtg 300 gagagacca atccagccaa tgacctctgt tacccaggga atttcaacaa ctatgaagag 360 ctgaaacacc tattgagcag ataaaccgg tttgagaaaa ttaagatcat ccccaaaagt 420 tcttggccag atcatgaagc ctcattagga gtgagctcag catgtccata ccagggagga 480 540 aaggaagtt accataatac caatcaagaa gatcttttgg tgctgtgggg aatccaccat 600 ccaaatgatg aggaagagca gacaaggatc tataaaaaacc caactaccta tatttccgtt 660 720 gggcagagtg gaaggtgga gttcttttgg acaattttaa aatcaaacga tacaataaac 780 tttgagagta atggaaattt cattgctcca gaaaatgcat acaaaattgt caagaaaggg 840 gactcaacaa ttatgaaaag tgagttggaa tatggtaact gcagcaccaa gtgtcaaact 900 ccagtagggg cgataaactc cagtatgcca ttccacaca tccaccctct caccatcggg 960 gatgcccca atatgtgaa atcaacaga ttagtccttg ctactggggct cagaaatagc 1020 cctcaggag agggagag aaaaagaga ggactttg gagctatagc aggttttata 1080 gagggaggat ggcagggaat ggtagatggt tggtaggtt accaccatag caacgagcag 1140 gggagtgggt acgctgcaga cagagaatcc actcaaagg caatagatgg agtcaccaat 1200 aaggtcact caatcattga aaatgaat actcagttg aggctgttgg aagggaattt 1260 aaacttgg aaagagaat agaaattta aaaagaga tggagacgg gtttctagat 1320 gtctggactt ataatgctga acttctggtt ctcatggaaa atgagaac tctagacttt 1380 catgactcaa atgtcagaa cctttacgac aaggtgcgac tacagcttag ggacaatgca 1440 aaggagcttg gtaacggttg ttcgagttc tatcacagat gcgataatga atgtatgga 1500 agtgtaagaa acggaacgta tgactacccg cagtattcag aagaagcaag attaaaaga 1560 Gaggaata gtggagtaa attggaatca atggaactt accaatact atcaatttat 1620 tcaacagtgg caagttccct agcactggca atcatagtgg ctggtctatt tttatggatg 1680 tgctccaatg gatcgttaca atgcagaatt tgcatttaa 1719 <210> 7 <211> 690 <212> PRT <213> Artifical sequence <400> 7 Met Glu Thr Ala Ser Leu Ile Thr Ile Leu Leu Val Val Thr Gly Ser 1 5 10 15 Ser Ala Asp Lys Ile Cys Ile Gly Tyr Gln Ser Thr Asn Ser Thr Glu 20 25 30 Thr Val Asp Thr Leu Thr Glu Asn Asn Val Pro Val Thr His Ala Lys 35 40 45 Glu Leu Leu His Thr Glu His Asn Gly Met Leu Cys Ala Thr Ser Leu 50 55 60 Gly Gln Pro Leu Ile Leu Asp Thr Cys Thr Ile Glu Gly Leu Ile Tyr 65 70 75 80 Gly Asn Pro Ser Cys Asp Ile Leu Leu Gly Gly Arg Glu Trp Ser Tyr 85 90 95 Ile Val Glu Arg Pro Ser Ala Val Asn Gly Leu Cys Tyr Pro Gly Asn 100 105 110 Val Glu Asn Leu Glu Glu Leu Arg Ser Leu Phe Ser Ser Ala Lys Ser 115 120 125 Tyr Gln Arg Ile Gln Ile Phe Pro Asp Thr Ile Trp Asn Val Ser Tyr 130 135 140 Ser Gly Thr Ser Lys Ala Cys Ser Asp Ser Phe Tyr Arg Ser Met Arg 145 150 155 160 Trp Leu Thr Gln Lys Asn Asn Ala Tyr Pro Ile Gln Asp Ala Gln Tyr 165 170 175 Thr Asn Asn Gln Glu Lys Asn Ile Leu Phe Met Trp Gly Ile Asn His 180 185 190 Pro Pro Thr Asp Thr Ala Gln Thr Asn Leu Tyr Thr Arg Thr Asp Thr 195 200 205 Thr Thr Ser Val Ala Thr Glu Glu Ile Asn Arg Thr Phe Lys Pro Leu 210 215 220 Ile Gly Pro Arg Pro Leu Val Asn Gly Leu Met Gly Arg Ile Asn Tyr 225 230 235 240 Tyr Trp Ser Val Leu Lys Pro Gly Gln Thr Leu Arg Ile Lys Ser Asn 245 250 255 Gly Asn Leu Ile Ala Pro Trp Tyr Gly His Ile Leu Ser Gly Glu Ser 260 265 270 His Gly Arg Ile Leu Lys Thr Asp Leu Lys Arg Gly Ser Cys Thr Val 275 280 285 Gln Cys Gln Thr Glu Lys Gly Gly Leu Asn Thr Thr Leu Pro Phe Gln 290 295 300 Asn Val Ser Lys Tyr Ala Phe Gly Asn Cys Ser Lys Tyr Ile Gly Ile 305 310 315 320 Lys Ser Leu Lys Leu Ala Val Gly Leu Arg Asn Val Pro Ser Arg Ser 325 330 335 Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp 340 345 350 Ser Gly Leu Val Ala Gly Trp Tyr Gly Phe Gln His Ser Asn Asn Gln 355 360 365 Gly Val Gly Met Ala Ala Asp Arg Asp Ser Thr Gln Lys Ala Ile Asp 370 375 380 Lys Ile Thr Ser Lys Val Asn Asn Ile Val Asp Lys Met Asn Lys Gln 385 390 395 400 Tyr Glu Ile Ile Asp His Glu Phe Ser Glu Phe Glu Thr Arg Leu Asn 405 410 415 Met Ile Asn Asn Lys Ile Asp Asp Gln Ile Leu Asp Ile Trp Ala Tyr 420 425 430 Asn Ala Glu Leu Leu Val Leu Leu Glu Asn Gln Lys Thr Leu Asp Glu 435 440 445 His Asp Ala Asn Val Asn Asn Leu Tyr Asn Lys Val Lys Arg Ala Leu 450 455 460 Gly Ser Asn Ala Val Glu Asp Gly Lys Gly Cys Phe Glu Leu Tyr His 465 470 475 480 Lys Cys Asp Asp Gln Cys Met Glu Thr Ile Arg Asn Gly Thr Tyr Asn 485 490 495 Arg Arg Lys Tyr Gln Glu Glu Ser Arg Leu Glu Arg Gln Lys Ile Glu 500 505 510 Gly Val Lys Leu Glu Ser Glu Gly Thr Tyr Lys Ile Ser Gly Gly Asp 515 520 525 Ile Ile Lys Leu Leu Asn Glu Gln Val Asn Lys Glu Met Gln Ser Ser 530 535 540 Asn Leu Tyr Met Ser Met Ser Ser Trp Cys Tyr Thr His Ser Leu Asp 545 550 555 560 Gly Ala Gly Leu Phe Leu Phe Asp His Ala Ala Glu Glu Tyr Glu His 565 570 575 Ala Lys Lys Leu Ile Ile Phe Leu Asn Glu Asn Asn Val Pro Val Gln 580,585,590 Leu Thr Ser Ile Ser Ala Pro Glu His Lys Phe Glu Gly Leu Thr Gln 595,600,605 I Phe Gln Lys Ala Tyr Glu His Glu Gln His Ile Ser Glu Ser Ile 610 615 620 Asn Asn Ile Val Asp His Ala Ile Lys Ser Lys Asp His Ala Thr Phe 625 630 635 640 Asn Phe Leu Gln Trp Tyr Val Ala Glu Gln His Glu Glu Glu Val Leu 645,650,655 Phe Lys Asp With Leu Asp Lys With Glu Leu And Gly Asn Glu Asn His 660,665,670 Gly Leu Tyr Leu Ala Asp Gln Tyr Val Lys Gly Ile Ala Lys Ser Arg 675,680,685 Lys Ser 690 <210> 8 <211> 2053 <212> DNA <213> Artificial sequence <400> 8 repeat catcactgat aactatacta ctagtagta repeat tgcactag 60 atctgcatcg gctatcaatc aaaaactcc acagaactg tagacacact aacagaaaac 120 aatgtccctg tgacacatgc caaagaattg ctccacacag agcataatgg gatgctgtgt 180 gcaacaagct tgggacaacc tcttattcta gacacttgta ccattgaagg actaatctat 240 ggcaatcctt cttgtgatat attgttggga ggaagagaat ggtcctatat cgtcgagaga 300 ccatcagctg ttaacggatt gtgttatccc gggaatgtag aaaatctaga agagctaagg 360 tcactcttta gttctgctaa gtcttatcaa aggatccaga ttttcccaga cacaatctgg 420 aatgtgtctt atagtgggac aagcaaggca tgttcggatt cattctacag aagcatgaga 480 tggttgactc aaaagaacaa cgcttaccct attcaagacg cccaatacac aaataatcaa 540 gaaaagaaca ttcttttcat gtggggcata aatcacccac ccactgacac tgcacagaca 600 aatctgtaca caagaaccga cacaacaacg agtgtggcaa cagaagaaat aaataggacc 660 ttcaaaccat tgataggacc aaggcctctt gtcaacggtt tgatgggaag aattaattat 720 tattggtcag tattaaaacc gggtcaaaca ctgcgaataa aatctaatgg aaatctaata 780 gctccatggt atggacacat tctttcagga gagagccacg ggagaatcct gaagactgac 840 ttaaaaagag gtagctgcac agtgcaatgt cagacagaga agggtggctt aaacacaaca 900 ttgccattcc aaaatgtgag tagtatgca tttggaaact gctcaaaata cattggcata 960 aagagtctca aacttgcagt tggtctgagg aatgtacctt ctagatccag tagaggacta 1020 ttcggggcca tagcaggatt catagaggga ggttggtcag gactagttgc tggttggtat 1080 gggttccagc attcaataa ccaaggggtt ggtatggcag cagataggga ctcaacccaa 1140 aaggcaattg ataaaataac atccaaagtg aataacatag tagacaaaat gaacaagcag 1200 1260 aagattgacg atcaaatcct ggatatatgg gcatataatg cagaattgct agttctgctt 1320 gaaaccaga aaacactcga tgagcatgat ccaaatgtaa acaatttgta caataaagtg 1380 aagagggcat tgggttccaa tgcggtggaa gatgggaaag gatgtttcga gctataccac 1440 aaatgtgatg accaatgcat ggagacaatt cggaacggga cctacaacag aaaggatt 1500 caagaggagt caagattaga aagacagaaa atagaggggg tcaagctgga attccggtgg 1560 cgacatcatc aagctgctga acgaacaggt gaacaaggag atgcagtcca gcaacctgta 1620 catgtctatg tcttcatggt gctacaccca ctcactggac ggagctggtc tgttcctgtt 1680 cgaccacgct gccgaggaat acgaacacgc caagaagctg atcatcttcc tgaacgagaa 1740 caacgtgcct gtccagctga cctccatcag cgctcccgaa cacaagttcg agggtctgac 1800 tcaaatcttc cagaaggcct acgaacacga gcagcacatc tctgaatcaa tcaacaacat 1860 cgtggaccac gctatcaaga gcaaggacca cgccactttc aacttcctgc aatggtacgt 1920 ggctgagcag cacgaggaag aggtcctgtt caaggacatc ctggacaaga tcgaactgat 1980 cggcaacgag aaccacggac tgtacctggc tgaccagtac gtcaagggca tcgccaagtc 2040 ccgcaagagc city 2053 <210> 9 <211> 698 <212> PRT <213> Artificial sequence <400> 9 Put Glu Lys Ile Val Leu Leu Leu Ala Ile Val Ser Leu Val Lys Ser 1 5 10 15 Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val 20 25 30 Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile 35 40 45 Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asp Gly Val Lys 50 55 60 Pro Leu Ile Leu Arg Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80 Pro Met Cys Asp Glu Phe Pro Asn Val Ser Glu Trp Ser Tyr Ile Val 85 90 95 Glu Lys Thr Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn 100 105 110 Asn Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn Arg Phe Glu 115 120 125 Lys Ile Lys Ile Ile Pro Lys Ser Ser Trp Pro Asp His Glu Ala Ser 130 135 140 Leu Gly Val Ser Ser Ala Cys Pro Tyr Gln Gly Gly Pro Ser Phe Tyr 145 150 155 160 Arg Asn Val Val Trp Leu Ile Lys Lys Asn Asn Thr Tyr Pro Thr Ile 165 170 175 Lys Glu Ser Tyr His Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp 180 185 190 Gly Ile His His Pro Asn Asp Glu Glu Glu Gln Thr Arg Ile Tyr Lys 195 200 205 Asn Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220 Leu Val Pro Lys Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly 225 230 235 240 Arg Val Glu Phe Phe Trp Thr Ile Leu Lys Ser Asn Asp Thr Ile Asn 245 250 255 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Asn Ala Tyr Lys Ile 260 265 270 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Leu Glu Tyr Gly 275 280 285 Asn Cys Ser Thr Lys Cys Gln Thr Pro Val Gly Ala Ile Asn Ser Ser 290 295 300 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320 Tyr Val Lys Ser Asn Arg Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335 Pro Gln Gly Glu Gly Arg Arg Lys Lys Arg Gly Leu Phe Gly Ala Ile 340 345 350 Ala Gly Phe Ile Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr 355 360 365 Gly Tyr His His Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Arg 370 375 380 Glu Ser Thr Gln Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser 385 390 395 400 Ile Ile Asp Lys Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe 405 410 415 Asn Asn Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp 420 425 430 Gly Phe Leu Asp Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met 435 440 445 Glu Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu 450 455 460 Tyr Asp Lys Val Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly 465 470 475 480 Asn Gly Cys Phe Glu Phe Tyr His Arg Cys Asp Asn Glu Cys Met Glu 485 490 495 Ser Val Arg Asn Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala 500 505 510 Arg Leu Lys Arg Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly 515 520 525 Thr Tyr Gln Ile Ser Gly Gly Asp Ile Ile Lys Leu Leu Asn Glu Gln 530 535 540 Val Asn Lys Glu Met Gln Ser Ser Asn Leu Tyr Met Ser Met Ser Ser 545 550 555 560 Trp Cys Tyr Thr His Ser Leu Asp Gly Ala Gly Leu Phe Leu Phe Asp 565 570 575 His Ala Ala Glu Glu Tyr Glu His Ala Lys Lys Leu Ile Ile Phe Leu 580 585 590 Asn Glu Asn Asn Val Pro Val Gln Leu Thr Ser Ile Ser Ala Pro Glu 595 600 605 His Lys Phe Glu Gly Leu Thr Gln Ile Phe Gln Lys Ala Tyr Glu His 610 615 620 Glu Gln His Ile Ser Glu Ser Ile Asn Asn Ile Val Asp His Ala Ile 625 630 635 640 Lys Ser Lys Asp His Ala Thr Phe Asn Phe Leu Gln Trp Tyr Val Ala 645 650 655 Glu Gln His Glu Glu Glu Val Leu Phe Lys Asp Ile Leu Asp Lys Ile 660 665 670 Glu Leu Ile Gly Asn Glu Asn His Gly Leu Tyr Leu Ala Asp Gln Tyr 675 680 685 Val Lys Gly Ile Ala Lys Ser Arg Lys Ser 690 695 <210> 10 <211> 2097 <212> DNA <213> Artificial sequence <400> 10 atggagaaaa tagtgcttct tcttgcaata gtcagtcttg ttaaaagtga tcagatttgc 60 attggttacc atgcaaacaa ctcaacagag caggttgaca caataatgga aaagaacgtc 120 actgttacac acgctcaaga catactggaa aagacacaca acggggaaact ctgcgatcta 180 gatggagtga agcctctaat tttaagagat tgtagtgtag ctggatggct cctcggggaac 240 ccaatgtgtg acgaattccc caatgtgtcg gaatggtcct acatagtgga gaagaccaat 300 ccagccaatg acctctgtta ccagggaat ttcaacaact atgaagagct gaaacaccta 360 ttgagcagaa taaaccggtt tgagaaaatt aagatcatcc ccaaaagttc ttggccagat 420 catgaagcct cattaggagt gagctcagca tgtccatacc agggaggacc ctcctttat 480 agaaatgtgg tatggcttat caaaaagaac aatacatacc caacaataaa ggaaagttac 540 cataatacca atcaagaaga tcttttggtg ctgtgggggaa tccaccatcc aaatgatgag 600 gaagcaga caaggatcta taaaaaccca actacctata tttccgttgg gacatcaaca 660 720 780 ggaaatttca ttgctccaga aaatgcatac aaaattgtca agaaaggga ctcaacaatt 840 atgaaaagtg agttggata tggtaactgc agcaccaagt gtcaaactcc agtaggggcg 900 ataaactcca gtatgccatt ccacaacatc caccctctca ccatcggga atgcccccaaa 960 tatgtgaaat caaacagatt agtccttgct actgggctca gaatagccc tcaaggagag 1020 ggaagagaa aaaagagagg actatttgga gctatagcag gttttataga gggaggatgg 1080 cagggaatgg tagatggttg gtatgggtac caccatagca acgagcaggg gagtgggtac 1140 gctgcagaca gagaatccac tcaaaggca atagatggag tcaccataa ggtcaactca 1200 atcattgaca aaatgaatac tcagttgag gctgttggaa gggaatttaa taacttggaa 1260 aagagaatag aaatttaaa caagagatg gagacggggtttctagatgt ctggacttat 1320 aatgctgaac ttctggttct catggaaat gagagaactc tagactttca tgactcaat 1380 gtcaagaacc tttacgacaa ggtgcgacta cagcttaggg acatgcaa ggagcttggt 1440 aacggttgtt tcgagttcta tcacagatgc gataatgaat gtatggaag tgtaagaac 1500 ggaacgtag actaccccgca gtattcagaa gaagcagat tAAaagaga ggaatagt 1560 ggagtaaat tggaatcaat aggaacttac caatatccg gtggcgacat catchcaagctg 1620 ctgaacgaac aggtgacaa ggagatgcag tccagcacc tgtacatgtc tatgtcttca 1680 tggtgctaca cccactcact gggacggagct gtctgttcc tgttcgacca cgctgccgag 1740 gatacgaac acgccaagaa gctgatcatc ttcctgaacg agaacaacgt gcctgtccag 1800 ctgacctcca tcagcgctcc cgaacacaag tcgaggtc tgactcaat cttccagaag 1860 gcctacgaac acgagcagca catctctgaa tcaatcaaca acatcgtgga ccacgctatc 1920 aagagcaagg accacgccac tttcaacttc ctgcaatggt acgtggctga gcagcacgag 1980 gaagaggtcc tgttcaagga catcctggac aagatcgaac tgatcggcaa cgagaaccac 2040 ggactgtacc tggctgacca gtacgtcaag ggcatcgcca agtcccgcaa gagctaa 2097 <210> 11 <211> 690 <212> PRT <213> Artifical sequence <400> 11 Met Glu Val Val Ser Leu Ile Thr Ile Leu Leu Val Val Thr Val Ser 1 5 10 15 Asn Ala Asp Lys Ile Cys Ile Gly Tyr Gln Ser Thr Asn Ser Thr Glu 20 25 30 Thr Val Asp Thr Leu Thr Glu Asn Asn Val Pro Val Thr His Ala Lys 35 40 45 Glu Leu Leu His Thr Glu His Asn Gly Met Leu Cys Ala Thr Gly Leu 50 55 60 Gly His Pro Leu Ile Leu Asp Thr Cys Thr Ile Glu Gly Leu Ile Tyr 65 70 75 80 Gly Asn Pro Ser Cys Asp Leu Leu Leu Gly Gly Arg Glu Trp Ser Tyr 85 90 95 Ile Val Glu Arg Pro Ser Ala Val Asn Gly Leu Cys Tyr Pro Gly Asn 100 105 110 Val Glu Asn Leu Glu Glu Leu Arg Ser Leu Phe Ser Ser Ala Arg Ser 115 120 125 Tyr Gln Arg Ile Gln Ile Phe Pro Asp Thr Ile Trp Asn Val Thr Tyr 130 135 140 Ser Gly Thr Ser Lys Ala Cys Ser Asp Ser Phe Tyr Arg Ser Met Arg 145 150 155 160 Trp Leu Thr Gln Lys Asn Asn Ala Tyr Pro Ile Gln Asp Ala Gln Tyr 165 170 175 Thr Asn Asn Gln Glu Lys Asn Ile Leu Phe Met Trp Gly Ile Asn His 180 185 190 Pro Pro Thr Asp Thr Val Gln Thr Asn Leu Tyr Thr Arg Thr Asp Thr 195 200 205 Thr Thr Ser Val Ala Thr Glu Glu Ile Asn Arg Thr Phe Lys Pro Leu 210 215 220 Ile Gly Pro Arg Pro Leu Val Asn Gly Leu Gln Gly Arg Ile Asp Tyr 225 230 235 240 Tyr Trp Ser Val Leu Lys Pro Gly Gln Thr Leu Arg Ile Arg Ser Asn 245 250 255 Gly Asn Leu Ile Ala Pro Trp Tyr Gly His Ile Leu Ser Gly Glu Ser 260 265 270 His Gly Arg Ile Leu Lys Thr Asp Leu Lys Arg Gly Ser Cys Thr Val 275 280 285 Gln Cys Gln Thr Glu Lys Gly Gly Leu Asn Thr Thr Leu Pro Phe Gln 290 295 300 Asn Val Ser Lys Tyr Ala Phe Gly Asn Cys Ser Lys Tyr Ile Gly Ile 305 310 315 320 Lys Ser Leu Lys Leu Ala Val Gly Leu Arg Asn Val Pro Ser Arg Ser 325 330 335 Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp 340 345 350 Ser Gly Leu Val Ala Gly Trp Tyr Gly Phe Gln His Ser Asn Asp Gln 355 360 365 Gly Val Gly Met Ala Ala Asp Arg Asp Ser Thr Gln Lys Ala Ile Asp 370 375 380 Lys Ile Thr Ser Lys Val Asn Asn Ile Val Asp Lys Met Asn Lys Gln 385 390 395 400 Tyr Glu Ile Ile Asp His Glu Phe Ser Glu Val Glu Ala Arg Leu Asn 405 410 415 Met Ile Asn Asn Lys Ile Asp Asp Gln Ile Gln Asp Ile Trp Ala Tyr 420 425 430 Asn Ala Glu Leu Leu Val Leu Leu Glu Asn Gln Lys Thr Leu Asp Glu 435 440 445 His Asp Ala Asn Val Asn Asn Leu Tyr Asn Lys Val Lys Arg Ala Leu 450 455 460 Gly Ser Asn Ala Val Glu Asp Gly Lys Gly Cys Phe Glu Leu Tyr His 465 470 475 480 Lys Cys Asp Asn Gln Cys Met Glu Thr Ile Arg Asn Gly Thr Tyr Asn 485 490 495 Arg Arg Lys Tyr Gln Glu Glu Ser Lys Leu Glu Arg Gln Lys Ile Glu 500 505 510 Gly Val Lys Leu Glu Ser Glu Gly Thr Tyr Lys Ile Ser Gly Gly Asp 515 520 525 Ile Ile Lys Leu Leu Asn Glu Gln Val Asn Lys Glu Met Gln Ser Ser 530 535 540 Asn Leu Tyr Met Ser Met Ser Ser Trp Cys Tyr Thr His Ser Leu Asp 545 550 555 560 Gly Ala Gly Leu Phe Leu Phe Asp His Ala Ala Glu Glu Tyr Glu His 565 570 575 Ala Lys Lys Leu Ile Ile Phe Leu Asn Glu Asn Asn Val Pro Val Gln 580 585 590 Leu Thr Ser Ile Ser Ala Pro Glu His Lys Phe Glu Gly Leu Thr Gln 595 600 605 Ile Phe Gln Lys Ala Tyr Glu His Glu Gln His Ile Ser Glu Ser Ile 610 615 620 Asn Asn Ile Val Asp His Ala Ile Lys Ser Lys Asp His Ala Thr Phe 625 630 635 640 Asn Phe Leu Gln Trp Tyr Val Ala Glu Gln His Glu Glu Glu Val Leu 645 650 655 Phe Lys Asp Ile Leu Asp Lys Ile Glu Leu Ile Gly Asn Glu Asn His 660 665 670 Gly Leu Tyr Leu Ala Asp Gln Tyr Val Lys Gly Ile Ala Lys Ser Arg 675 680 685 Lys Ser 690 <210> 12 <211> 2073 <212> DNA <213> Artifical sequence <400> 12 atggaagtag taagtctgat aaccattctg ctcgtcgtca ccgtctcaaa cgctgataaa 60 atctgcatcg gctaccaatc cacaaatagc actgaaaccg tggacacgct gacagagaac 120 aatgtgccgg ttactcacgc taaagaactg ttgcacaccg agcataacgg tatgctctgc 180 gccactggtt taggacatcc tcttatcctg gacacttgca ccatcgaagg tttaatttac 240 ggaaacccat cctgtgatct cttacttggt ggacgtgaat ggtcatacat tgtggagagg 300 ccttctgctg ttaatggact ttgctatcca ggcaacgtcg agaatttaga agagcttcgc 360 agcctgttct catctgccag atcctaccaa agaatccaaa tcttccctga cacaatatgg 420 aacgtaacgt acagcggtac atccaaagct tgttcagatt ctttctatag atcaatgcgc 480 tggctcactc aaaagaacaa tgcttaccca atccaagatg cccagtatac caacaatcag 540 gaaaagaaca tcctttttat gtggggaatt aatcaccctc caacggacac agtccaaact 600 aatctgtaca ctcgtaccga tacaactacc tctgtagcca cggaagagat aaaccgtaca 660 ttcaaacctt taatcggccc gaggcccttg gtgaatggtc tccaaggaag aattgactac 720 tattggtcgg ttcttaagcc gggtcagacg ctgcgtata ggagtaacgg aaatttaatc gctccctggt acggccacat tctttcgggc gaaagtcatg gtagaatatt aaagaccgat cttaagcgcg gcagctgcac ggtccaatgt cagacagaga agggcggtct gaacacgaca ttgccgttcc agaatgtatc caatacgca tttggtaact gctcgaagta tattggtatc aaaagtttga agctcgcggt gggactcaga aatgttccct cgcgtagctc caggggctta ttcggtgcaa tagcgggttt tatcgaagga ggctggtcag gactcgtggc aggatggtac 1080 ggcttccaac actctacga ccaggggcgtt ggtatggctg ccgacaggga ttcaacgcaa aaagccatcg father atctaaggtc aacaacatag tagcaaaat gaacaagcag 1260. ttgaatca ttgatcatga gttttcagaa gtggaggcta gactgaacat gatcaacaac 1320. aaaatcgacg atcaaataca ggacatctgg gcttataacg ccgaactgtt ggttctctta gagaatcaaa agaccttgga cgaacacgat gctaacgtca acaacttgta caacaaagta aagagagcac tcggatcga cgcggtgga gacggaaaag gctgtttcga gttgtatcat aagtgcgata atcagtgtat ggaaactatt cgcaacggca cctacaatag acgcaaatat 1500 caagaagaga gtaagctcga acgtcagaaa atagagggcg ttaagctgga aagcgagggt 1560 acatacaaga ttccggtgg cgacatcatc aagctgctga acgaacaggt gaacaaggag 1620 atgcagtcca gcaacctgta catgtctatg tcttcatggt gctacaccca ctcactggac 1680 ggagctggtc tgttcctgtt cgaccacgct gccgaggaat acgaacacgc caagaagctg 1740 atcatcttcc tgaacgagaa caacgtgcct gtccagctga cctccatcag cgctcccgaa 1800 cacaagttcg agggtctgac tcaaatcttc cagaaggcct acgaacacga gcagcacatc 1860 tctgaatcaa tcaacaacat cgtggaccac gctatcaaga gcaaggacca cgccactttc 1920 aacttcctgc aatggtacgt ggctgagcag cacgaggaag aggtcctgtt caaggacatc 1980 ctggacaaga tcgaactgat cggcaacgag aaccacggac tgtacctggc tgaccagtac 2040 gtcaagggca tcgccaagtc ccgcaagagc taa 2073 <210> 13 <211> 730 <212> PRT <213> Artificial sequence <400> 13 Met Glu Lys Ile Val Leu Leu Phe Ala Ile Val Ser Leu Val Lys Ser 1 5 10 15 Asp His Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val 20 25 30 Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile 35 40 45 Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asn Gly Val Lys 50 55 60 Pro Leu Ile Leu Lys Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80 Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val 85 90 95 Glu Lys Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn 100 105 110 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu 115 120 125 Lys Ile Gln Ile Ile Pro Lys Asp Ser Trp Pro Asp His Glu Ala Ser 130 135 140 Leu Gly Val Ser Ala Ala Cys Pro Tyr Gln Gly Asn Ser Ser Phe Phe 145 150 155 160 Arg Asn Val Val Trp Leu Ile Lys Lys Asp Asn Ala Tyr Pro Thr Ile 165 170 175 Lys Lys Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp 180 185 190 Gly Ile His His Pro Asn Asp Glu Ala Glu Gln Thr Arg Leu Tyr Gln 195 200 205 Asn Pro Thr Thr Tyr Val Ser Ile Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220 Leu Val Pro Lys Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly 225 230 235 240 Arg Ile Asp Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn 245 250 255 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 260 265 270 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Val Glu Tyr Gly 275 280 285 Asn Cys Asn Thr Arg Cys Gln Thr Pro Ile Gly Ala Ile Asn Ser Ser 290 295 300 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320 Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335 Pro Gln Arg Glu Gly Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile 340 345 350 Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His 355 360 365 Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln 370 375 380 Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile Ile Asp Lys 385 390 395 400 Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn Asn Leu Glu 405 410 415 Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp Gly Phe Leu Asp 420 425 430 Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg 435 440 445 Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val 450 455 460 Arg Leu Gln Leu Lys Asp Asn Ala Lys Glu Leu Gly Asn Gly Cys Phe 465 470 475 480 Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Arg Asn 485 490 495 Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg Leu Lys Arg 500 505 510 Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Ile Tyr Gln Ile 515 520 525 Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Ala Ile Met 530 535 540 Met Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser Leu Gln Cys 545 550 555 560 Arg Ile Cys Ile Ser Gly Gly Asp Ile Ile Lys Leu Leu Asn Glu Gln 565 570 575 Val Asn Lys Glu Met Gln Ser Ser Asn Leu Tyr Met Ser Met Ser Ser 580 585 590 Trp Cys Tyr Thr His Ser Leu Asp Gly Ala Gly Leu Phe Leu Phe Asp 595 600 605 His Ala Ala Glu Glu Tyr Glu His Ala Lys Lys Leu Ile Ile Phe Leu 610 615 620 Asn Glu Asn Asn Val Pro Val Gln Leu Thr Ser Ile Ser Ala Pro Glu 625 630 635 640 His Lys Phe Glu Gly Leu Thr Gln Ile Phe Gln Lys Ala Tyr Glu His 645,650,655 Glu Gln His Protein Ser Glu Ser Protein Asn Protein Val Asp Protein Protein 660,665,670 Lys Ser Lys Asp His Ala Thr Phe Asn Phe Leu Gln Trp Tyr Val Ala 675,680,685 Glu Gln His Glu Glu Glu Val Leu Phe Lys Asp Ile Leu Asp Lys Ile 690,695,700 Leu Glu With Gly Asn Glu Asn His Gly Leu Tyr Leu Asp Gln Tyr 705 710 715 720 Val Lys Gly Ile Ala Lys Ser Arg Lys Ser 725,730 <210> 14 <211> 2193 <212> DNA <213> Artificial sequence <400> 14 atggaaaaaa tcgtgctgct gttcgcaatc gtgagcctgg tgaagagtga ccatatctgt 60 atcgggtatc atgctaataa ttctactgaa caggtggata ccattatgga gagaacgtg 120 actgtgaccc acgctcagga catcctggag aaaacacata acggcaagct gtgcgatctg 180 aatggagtga aacccctgat cctgaaggac tgctcagtgg caggctggct gctgggaaac 240 cccatgtgtg atgagttcat caatgtgcct gaatggtcct acattgtgga gaagccaac 300 cctgctaatg atctgtgcta cccaggcaac ttcaatgact atgaggaact gaagcacctg 360 ctgtccagaa tcaaccattt cgaaaagatc cagatcattc ccaaggattc ttggcctgac 420 cacgaggcct cactgggtgt gagtgccgct tgtccatacc agggaaacag ctccttcttt 480 aggaatgtgg tgtggctgat taagaaagac aacgcttacc ccactatcaa gaaatcttac 540 aaaacacca accaggaga tctgctgggtg ctgtgggggaa tccaccatcc aaacgacgag 600 ggaaagaga cacgcctgta ccagaatccc accacatatg tgagcattgg gacatccact 660 ctgaaccagc gcctggtgcc taaaatcgca actcggtcca aggtgaacgg ccagtctgga 720 cggatcgatt tcttttggac cattctgaag cctaacgacg ccatcaattt cgaatccaac 780 ggcaatttta tcgcaccaga gtacgcctac aagatcgtga aagaagaga ttctactatc 840 atgaagtcag aggtggata cgggaactgc aatacccgct gtcagacacc aatcggtgcc 900 attaactctt caatgccatt tcacaatatc catcccctga caattgggga gtgccccaag 960 tatgtgaaaa gcaacaagct ggtgctggct actggtctga gaaacagccc tcagagggag 1020 ggtaggggtc tgttcggggc tatcgcaggt tttattgagg gcggatggca gggaatggtg 1080 gatgggtggt acggttatca ccatagtaac gaacagggca gcggatacgc agccgataaa 1140 gagagtacac agaaggccat tgacggagtg actaacaaag tgaatagcat cattgacaag 1200 atgaacaccc agttcgaggc tgtggggagg gaatttaaca atctggagag aaggatcgaa 1260 aacctgaata agaaaatgga agatggcttc ctggacgtgt ggacctacaa cgcagagctg 1320 ctggtgctga tggagaatga aagaacactg gattttcacg acagcaacgt gaaaaatctg 1380 tatgataaag tgaggctcca gctgaaagac aacgccaagg aactggggaa tggttgtttc 1440 gagttttacc ataagtgcga taacgagtgt atggaatctg tgagaaatgg cacttacgac 1500 tatcctcagt attcagagga agctagactg aaaagggagg aaatttcagg ggtgaagctg 1560 gagagtatcg gtatttacca gatcctgtcc atttattcta ccgtggctag tagcctggtg 1620 ctggcaatca tgatggctgg gctgtccctg tggatgtgta gcaatggaag tctccagtgt 1680 cggatttgta tctccggtgg cgacatcatc aagctgctga acgaacaggt gaacaaggag 1740 atgcagtcca gcaacctgta catgtctatg tcttcatggt gctacaccca ctcactggac 1800 ggagctggtc tgttcctgtt cgaccacgct gccgaggaat acgaacacgc caagaagctg 1860 atcatcttcc tgaacgagaa caacgtgcct gtccagctga cctccatcag cgctcccgaa 1920 cacaagttcg agggtctgac tcaaatcttc cagaaggcct acgaacacga gcagcacatc 1980 tctgaatcaa tcaacaacat cgtggaccac gctatcaaga gcaaggacca cgccactttc 2040 aacttcctgc aatggtacgt ggctgagcag cacgaggaag aggtcctgtt caaggacatc 2100 ctggacaaga tcgaactgat cggcaacgag aaccacggac tgtacctggc tgaccagtac 2160 gtcaagggca tcgccaagtc ccgcaagagc taa 2193 <210> 15 <211> 690 <212> PRT <213> Artificial sequence <400> 15 Met Glu Val Val Ser Leu Ile Thr Ile Leu Leu Val Val Thr Val Ser 1 5 10 15 Asn Ala Asp Lys Ile Cys Ile Gly Tyr Gln Ser Thr Asn Ser Thr Glu 20 25 30 Thr Val Asp Thr Leu Thr Glu Asn Asp Val Pro Val Thr His Ala Lys 35 40 45 Glu Leu Leu His Thr Glu His Asn Gly Met Leu Cys Ala Thr Gly Leu 50 55 60 Gly His Pro Leu Ile Leu Asp Thr Cys Thr Ile Glu Gly Leu Ile Tyr 65 70 75 80 Gly Asn Pro Ser Cys Asp Leu Leu Leu Gly Gly Arg Glu Trp Ser Tyr 85 90 95 Ile Val Glu Arg Pro Ser Ala Val Asn Gly Leu Cys Tyr Pro Gly Asn 100 105 110 Val Glu Asn Leu Glu Glu Leu Arg Ser Leu Phe Ser Ser Ala Arg Ser 115 120 125 Tyr Gln Arg Ile Gln Ile Phe Pro Asp Thr Ile Trp Asn Val Thr Tyr 130 135 140 Ser Gly Thr Ser Lys Ala Cys Ser Asp Ser Phe Tyr Arg Ser Met Arg 145 150 155 160 Trp Leu Thr Gln Lys Asn Asn Ala Tyr Pro Ile Gln Asp Ala Gln Tyr 165 170 175 Thr Asn Asn Gln Glu Lys Asn Ile Leu Phe Met Trp Gly Ile Asn His 180 185 190 Pro Pro Thr Asp Thr Val Gln Thr Asn Leu Tyr Thr Arg Thr Asp Thr 195 200 205 Thr Thr Ser Val Ala Thr Glu Glu Ile Asn Arg Thr Phe Lys Pro Leu 210 215 220 Ile Gly Pro Arg Pro Leu Val Asn Gly Leu Gln Gly Arg Ile Asp Tyr 225 230 235 240 Tyr Trp Ser Val Leu Lys Pro Gly Gln Thr Leu Arg Ile Arg Ser Asn 245 250 255 Gly Asn Leu Ile Ala Pro Trp Tyr Gly His Ile Leu Ser Gly Glu Ser 260 265 270 His Gly Arg Ile Leu Lys Thr Asp Leu Lys Arg Gly Ser Cys Thr Val 275 280 285 Gln Cys Gln Thr Glu Lys Gly Gly Leu Asn Thr Thr Leu Pro Phe Gln 290 295 300 Asn Val Ser Lys Tyr Ala Phe Gly Asn Cys Ser Lys Tyr Ile Gly Ile 305 310 315 320 Lys Ser Leu Lys Leu Ala Val Gly Leu Arg Asn Val Pro Ser Arg Ser 325 330 335 Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp 340 345 350 Ser Gly Leu Val Ala Gly Trp Tyr Gly Phe Gln His Ser Asn Asp Gln 355 360 365 Gly Val Gly Met Ala Ala Asp Arg Asp Ser Thr Gln Lys Ala Ile Asp 370 375 380 Lys Ile Thr Ser Lys Val Asn Asn Ile Val Asp Lys Met Asn Lys Gln 385 390 395 400 Tyr Glu Ile Ile Asp His Glu Phe Ser Glu Val Glu Ala Arg Leu Asn 405 410 415 Met Ile Asn Asn Lys Ile Asp Asp Gln Ile Gln Asp Ile Trp Ala Tyr 420 425 430 Asn Ala Glu Leu Leu Val Leu Leu Glu Asn Gln Lys Thr Leu Asp Glu 435 440 445 His Asp Ala Asn Val Asn Asn Leu Tyr Asn Lys Val Lys Arg Ala Leu 450 455 460 Gly Ser Asn Ala Val Glu Asp Gly Lys Gly Cys Phe Glu Leu Tyr His 465 470 475 480 Lys Cys Asp Asn Gln Cys Met Glu Thr Ile Arg Asn Gly Thr Tyr Asn 485 490 495 Arg Arg Lys Tyr Gln Glu Glu Ser Lys Leu Glu Arg Gln Lys Ile Glu 500 505 510 Gly Val Lys Leu Glu Ser Glu Gly Thr Tyr Lys Ile Ser Gly Gly Asp 515 520 525 Ile Ile Lys Leu Leu Asn Glu Gln Val Asn Lys Glu Met Gln Ser Ser 530 535 540 Asn Leu Tyr Met Ser Met Ser Ser Trp Cys Tyr Thr His Ser Leu Asp 545 550 555 560 Gly Ala Gly Leu Phe Leu Phe Asp His Ala Ala Glu Glu Tyr Glu His 565 570 575 Ala Lys Lys Leu Ile Ile Phe Leu Asn Glu Asn Asn Val Pro Val Gln 580 585 590 Leu Thr Ser Ile Ser Ala Pro Glu His Lys Phe Glu Gly Leu Thr Gln 595 600 605 Ile Phe Gln Lys Ala Tyr Glu His Glu Gln His Ile Ser Glu Ser Ile 610 615 620 Asn Asn Ile Val Asp His Ala Ile Lys Ser Lys Asp His Ala Thr Phe 625 630 635 640 Asn Phe Leu Gln Trp Tyr Val Ala Glu Gln His Glu Glu Glu Val Leu 645,650,655 Phe Lys Asp Ile Leu Asp Lys Ile Glu Leu Ile Gly Asn Glu Asn His 660 665 670 Gly Leu Tyr Leu Ala Asp Gln Tyr Val Lys Gly Ile Ala Lys Ser Arg 675 680 685 Lys Ser 690 <210> 16 <211> 2073 <212> DNA <213> Artificial sequence <400> 16 atggaagtag taagtctgat aaccattctg ctcgtcgtca ccgtctcaaa cgctgataaa 60 atctgcatcg gctaccaatc cacaatagc actgaaaccg tggacacgct gacagagaac 120 gatgtgccgg ttactcacgc taaagaactg ttgcacaccg agcataacgg tatgctctgc 180 gccactggtt taggacatcc tcttatcctg gacacttgca ccatcgaagg tttaatttac 240 ggaaacccat cctgtgatct cttacttggt ggacgtgaat ggtcatacat tgtggagagg 300 ccttctgctg ttaatggact ttgctatcca ggcaacgtcg agaatttaga agagcttcgc 360 agcctgttct catctgccag atcctaccaa agaatccaaa tcttccctga caaatatgg 420 aacgtaacgt acagcggtac atccaaagct tgttcagatt ctttctatag atcaatgcgc 480 tggctcactc aaaagaacaa tgcttaccca atccaagatg cccagtatac caacaatcag 540 gaaaagaaca tcctttttat gtggggaatt aatcaccctc caacggacac agtccaaact 600 aatctgtaca ctcgtaccga tacaactacc tctgtagcca cggagaagat aaaccgtaca 660 ttcaaacctt taatcggccc gaggcccttg gtgaatggtc tccaaggaag aattgactac 720 tattggtcgg ttcttaagcc gggtcagacg ctgcgtataa ggagtaacgg aaatttaatc 780 gctccctggt acggccacat tctttcgggc gaaagtcatg gtagaatatt aaagaccgat 840 cttaagcgcg gcagctgcac ggtccaatgt cagacagaga agggcggtct gaacacgaca 900 ttgccgttcc agaatgtatc caaatacgca tttggtaact gctcgaagta tattggtatc 960 aaaagtttga agctcgcggt gggactcaga aatgttccct cgcgtagctc caggggctta 1020 ttcggtgcaa tagcgggttt tatcgaagga ggctggtcag gactcgtggc aggatggtac 1080 ggcttccaac actctaacga ccagggcgtt ggtatggctg ccgacaggga ttcaacgcaa 1140 aaagccatcg ataagataac atctaaggtc aacaacatag tagacaaaat gaacaagcag 1200 tacgaaatca ttgatcatga gttttcagaa gtggaggcta gactgaacat gatcaacaac 1260 aaaatcgacg atcaaataca ggacatctgg gcttataacg ccgaactgtt ggttctctta 1320 gagaatcaaa agaccttgga cgaacacgat gctaacgtca acaacttgta caacaaagta 1380 aagagagcac tcggatcgaa cgcggtggaa gacggaaaag gctgtttcga gttgtatcat 1440 aagtgcgata atcagtgtat ggaaactatt cgcaacggca cctacaatag acgcaaatat 1500 caagaagaga gtaagctcga acgtcagaaa atagagggcg ttaagctgga aagcgagggt 1560 acatacaaga tttccggtgg cgacatcatc aagctgctga acgaacaggt gaacaaggag 1620 atgcagtcca gcaacctgta catgtctatg tcttcatggt gctacaccca ctcactggac 1680 ggagctggtc tgttcctgtt cgaccacgct gccgaggaat acgaacacgc caagaagctg 1740 atcatcttcc tgaacgagaa caacgtgcct gtccagctga cctccatcag cgctcccgaa 1800 cacaagttcg agggtctgac tcaatctc cagaaggcct acgaacacga gcagcacacga 1860 tctgaatcaa cgtggaccac gctatcaga gcaaggacca cgccactttc 1920 aacttcctgc aatgtacgt ggctgagcag cacgaggaag aggtcctgtt caggacatc 1980 ctggacaaga tcgaacgat cggcaacgag aaccacggac tgtacctggc tgaccagtac 2040 gtcaagggca tcgccaagtc ccgcaaggc taa 2073 <210> 17 <211> 730 <212> PRT <213> Artificial sequence <400> 17 Met Glu Lys Ile Val Leu Phe Ala Ile Val Ser Leu Val Lys Ser 1 5 10 15 Asp Contains Cys Contains Gly Tyr Only Asn Asn Served Thr Glu Gln Val 20 25 30 Asp Thr Met Glu Lys Asn Value Only Gln Asp 35 40 45 Leu Glu Lys Thr His and Gly Lys Leu Cys Asp Leu Asn Gly Val Lys 50 55 60 Pro Leu Leu Lys Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80 Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val 85 90 95 Glu Lys Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn 100 105 110 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu 115 120 125 Lys Ile Gln Ile Ile Pro Lys Asp Ser Trp Pro Asp His Glu Ala Ser 130 135 140 Leu Gly Val Ser Ala Ala Cys Pro Tyr Gln Gly Asn Ser Ser Phe Phe 145 150 155 160 Arg Asn Val Val Trp Leu Ile Lys Lys Asp Asn Ala Tyr Pro Thr Ile 165 170 175 Lys Lys Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Ile Leu Trp 180 185 190 Gly Ile His His Pro Asn Asp Glu Ala Glu Gln Thr Arg Leu Tyr Gln 195 200 205 Asn Pro Thr Thr Tyr Val Ser Ile Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220 Leu Val Pro Lys Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly 225 230 235 240 Arg Ile Asp Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn 245 250 255 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 260 265 270 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Val Glu Tyr Gly 275 280 285 Asn Cys Asn Thr Arg Cys Gln Thr Pro Ile Gly Ala Ile Asn Ser Ser 290 295 300 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320 Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335 Pro Gln Arg Glu Gly Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile 340 345 350 Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His 355 360 365 Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln 370 375 380 Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile Ile Asp Lys 385 390 395 400 Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn Asn Leu Glu 405 410 415 Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp Gly Phe Leu Asp 420 425 430 Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg 435 440 445 Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val 450 455 460 Arg Leu Gln Leu Lys Asp Asn Ala Lys Glu Leu Gly Asn Gly Cys Phe 465 470 475 480 Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Arg Asn 485 490 495 Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg Leu Lys Arg 500 505 510 Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Ile Tyr Gln Ile 515 520 525 Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Ala Ile Met 530 535 540 Met Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser Leu Gln Cys 545 550 555 560 Arg Ile Cys Ile Ser Gly Gly Asp Ile Ile Lys Leu Leu Asn Glu Gln 565 570 575 Val Asn Lys Glu Met Gln Ser Ser Asn Leu Tyr Met Ser Met Ser Ser 580 585 590 Trp Cys Tyr Thr His Ser Leu Asp Gly Ala Gly Leu Phe Leu Phe Asp 595 600 605 His Ala Ala Glu Glu Tyr Glu His Ala Lys Lys Leu Ile Ile Phe Leu 610 615 620 Asn Glu Asn Asn Val Pro Val Gln Leu Thr Ser Ile Ser Ala Pro Glu 625 630 635 640 His Lys Phe Glu Gly Leu Thr Gln Ile Phe Gln Lys Ala Tyr Glu His 645 650 655 Glu Gln His Ile Ser Glu Ser Ile Asn Asn Ile Val Asp His Ala Ile 660 665 670 Lys Ser Lys Asp His Ala Thr Phe Asn Phe Leu Gln Trp Tyr Val Ala 675 680 685 Glu Gln His Glu Glu Glu Val Leu Phe Lys Asp Ile Leu Asp Lys Ile 690 695 700 Glu Leu Ile Gly Asn Glu Asn His Gly Leu Tyr Leu Ala Asp Gln Tyr 705,710,715,720 Val Lys Gly Ile Ala Lys Ser Arg Lys Ser 725 730 <210> 18 <211> 2193 <212> DNA <213> Artificial sequence <400> 18 atggaaaaaa tcgtgctgct gttcgcaatc gtgagcctgg tgaagagtga ccatatctgt 60 atcgggtatc atgctaataa ttctactgaa caggtggata ccattatgga gaagaacgtg 120 actgtgaccc acgctcagga catcctggag aaacacata acggcaagct gtgcgatctg 180 aatggagtga aacccctgat cctgaaggac tgctcagtgg caggctggct gctgggaaac 240 cccatgtgtg atgagttcat caatgtgcct gaatggtcct acattgtgga gaaagccaac 300 cctgctaatg atctgtgcta cccaggcaac ttcaatgact atgaggaact gaagcacctg 360 ctgtccagaa tcaaccattt cgaaaagatc cagatcattc ccaaggattc ttggcctgac 420 cacgaggcct cactgggtgt gagtgccgct tgtccatacc agggaaacag ctccttcttt 480 aggaatgtgg tgtggctgat taagaaagac aacgcttacc ccactatcaa gaaatcttac 540 aaaacacca accaggaga tctgctgatt ctgtgggggaa tccaccatcc aaacgacgag 600 ggaaagaga cacgcctgta ccagaatccc accacatatg tgagcattgg gacatccact 660 ctgaaccagc gcctggtgcc taaaatcgca actcggtcca aggtgaacgg ccagtctgga 720 cggatcgatt tcttttggac cattctgaag cctaacgacg ccatcaattt cgaatccaac 780 ggcaatttta tcgcaccaga gtacgcctac aagatcgtga aagaagaga ttctactatc 840 atgaagtcag aggtggata cgggaactgc aatacccgct gtcagacacc aatcggtgcc 900 attaactctt caatgccatt tcacaatatc catcccctga caattgggga gtgccccaag 960 tatgtgaaaa gcaacaagct ggtgctggct actggtctga gaacagccc tcagagggag 1020 ggtaggggtc tgttcggggc tatcgcaggt tttattgagg gcggatggca gggaatggtg 1080 gatgggtggt acggttatca ccatagtaac gaacagggca gcggatacgc agccgataaa 1140 gagagtacac agaaggccat tgacggagtg actaacaaag tgaatagcat cattgacaag 1200 atgaacaccc agttcgaggc tgtggggagg gaatttaaca atctggagag aaggatcgaa 1260 aacctgaata agaaaatgga agatggcttc ctggacgtgt ggacctacaa cgcagagctg 1320 ctggtgctga tggagaatga aagaacactg gattttcacg acagcaacgt gaaaaatctg 1380 tatgataaag tgaggctcca gctgaaagac aacgccaagg aactggggaa tggttgtttc 1440 gagttttacc ataagtgcga taacgagtgt atggaatctg tgagaaatgg cacttacgac 1500 tatcctcagt attcagagga agctagactg aaaagggagg aaatttcagg ggtgaagctg 1560 gagagtatcg gtatttacca gatcctgtcc atttattcta ccgtggctag tagcctggtg 1620 ctggcaatca tgatggctgg gctgtccctg tggatgtgta gcaatggaag tctccagtgt 1680 cggatttgta tctccggtgg cgacatcatc aagctgctga acgaacaggt gaacaaggag 1740 atgcagtcca gcaacctgta catgtctatg tcttcatggt gctacaccca ctcactggac 1800 ggagctggtc tgttcctgtt cgaccacgct gccgaggaat acgaacacgc caagaagctg 1860 atcatcttcc tgaacgagaa caacgtgcct gtccagctga cctccatcag cgctcccgaa 1920 cacaagttcg agggtctgac tcaatctc cagaaggcct acgaacacga gcagcacacga 1980 tctgaatcaa tcacacat cgtggaccac gctatcaga gcaaggacca cgccactttc 2040 aacttcctgc aatgtacgt ggctgagcag cacgaggaag aggtcctgtt caggacatc 2100 ctggacaaga tcgaacgat cggcaacgag aaccacggac tgtacctggc tgaccagtac 2160 gtcaagggca tcgccaagtc ccgcaaggc taa 2193 <210> 19 <211> 690 <212> PRT <213> Artificial sequence <400> 19 Met Glu Will Be Leu Ile Thr Leo Island Leu Will Thr Will Be 1 5 10 15 Asn Only Asp Lys Ile Cys Ile Gly Tyr Gln Server Thr Asn Serve Three Glu 20 25 30 Thr Val Asp Thr Leu Thr Glu Asn Asp Val Pro Val Thr His Thr Lys 35 40 45 Glu Leu Leu His Thr Glu His Asn Gly Met Leu Cys Ala Thr Gly Leu 50 55 60 Gly His Pro With Asp Thr Cys Thr With Glu Gly With Tyr 65 70 75 80 Gly Asn Pro Ser Cys Asp Leu Leu Leu Gly Gly Arg Glu Trp Ser Tyr 85 90 95 Ile Val Glu Arg Pro Ser Ala Val Asn Gly Leu Cys Tyr Pro Gly Asn 100 105 110 Val Glu Asn Leu Glu Glu Leu Arg Ser Leu Phe Ser Ser Ala Arg Ser 115 120 125 Tyr Gln Arg Ile Gln Ile Phe Pro Asp Thr Ile Trp Asn Val Thr Tyr 130 135 140 Ser Gly Thr Ser Lys Ala Cys Ser Asp Ser Phe Tyr Arg Ser Met Arg 145 150 155 160 Trp Leu Thr Gln Lys Asn Asn Ala Tyr Pro Ile Gln Asp Ala Gln Tyr 165 170 175 Thr Asn Asn Gln Glu Lys Asn Ile Leu Phe Met Trp Gly Ile Asn His 180 185 190 Pro Pro Thr Asp Thr Val Gln Thr Asn Leu Tyr Thr Arg Thr Asp Thr 195 200 205 Thr Thr Ser Val Ala Thr Glu Glu Ile Asn Arg Thr Phe Lys Pro Leu 210 215 220 Ile Gly Pro Arg Pro Leu Val Asn Gly Leu Gln Gly Arg Ile Asp Tyr 225 230 235 240 Tyr Trp Ser Val Leu Lys Pro Gly Gln Thr Leu Arg Ile Arg Ser Asn 245 250 255 Gly Asn Leu Ile Ala Pro Trp Tyr Gly His Ile Leu Ser Gly Glu Ser 260 265 270 His Gly Arg Ile Leu Lys Thr Asp Leu Lys Arg Gly Ser Cys Thr Val 275 280 285 Gln Cys Gln Thr Glu Lys Gly Gly Leu Asn Thr Thr Leu Pro Phe Gln 290 295 300 Asn Val Ser Lys Tyr Ala Phe Gly Asn Cys Ser Lys Tyr Ile Gly Ile 305 310 315 320 Lys Ser Leu Lys Leu Ala Val Gly Leu Arg Asn Val Pro Ser Arg Ser 325 330 335 Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp 340 345 350 Ser Gly Leu Val Ala Gly Trp Tyr Gly Phe Gln His Ser Asn Asp Gln 355 360 365 Gly Val Gly Met Ala Ala Asp Arg Asp Ser Thr Gln Lys Ala Ile Asp 370 375 380 Lys Ile Thr Ser Lys Val Asn Asn Ile Val Asp Lys Met Asn Lys Gln 385 390 395 400 Tyr Glu Ile Ile Asp His Glu Phe Ser Glu Val Glu Ala Arg Leu Asn 405 410 415 Met Ile Asn Asn Lys Ile Asp Asp Gln Ile Gln Asp Ile Trp Ala Tyr 420 425 430 Asn Ala Glu Leu Leu Val Leu Leu Glu Asn Gln Lys Thr Leu Asp Glu 435 440 445 His Asp Ala Asn Val Asn Asn Leu Tyr Asn Lys Val Lys Arg Ala Leu 450 455 460 Gly Ser Asn Ala Val Glu Asp Gly Lys Gly Cys Phe Glu Leu Tyr His 465 470 475 480 Lys Cys Asp Asn Gln Cys Met Glu Thr Ile Arg Asn Gly Thr Tyr Asn 485 490 495 Arg Arg Lys Tyr Gln Glu Glu Ser Lys Leu Glu Arg Gln Lys Ile Glu 500 505 510 Gly Val Lys Leu Glu Ser Glu Gly Thr Tyr Lys Ile Ser Gly Gly Asp 515 520 525 Ile Ile Lys Leu Leu Asn Glu Gln Val Asn Lys Glu Met Gln Ser Ser 530 535 540 Asn Leu Tyr Met Ser Met Ser Ser Trp Cys Tyr Thr His Ser Leu Asp 545 550 555 560 Gly Ala Gly Leu Phe Leu Phe Asp His Ala Ala Glu Glu Tyr Glu His 565 570 575 Ala Lys Lys Leu Ile Ile Phe Leu Asn Glu Asn Asn Val Pro Val Gln 580 585 590 Leu Thr Ser Ile Ser Ala Pro Glu His Lys Phe Glu Gly Leu Thr Gln 595 600 605 Ile Phe Gln Lys Ala Tyr Glu His Glu Gln His Ile Ser Glu Ser Ile 610 615 620 Asn Asn Ile Val Asp His Ala Ile Lys Ser Lys Asp His Ala Thr Phe 625 630 635 640 Asn Phe Leu Gln Trp Tyr Val Ala Glu Gln His Glu Glu Glu Val Leu 645 650 655 Phe Lys Asp Ile Leu Asp Lys Ile Glu Leu Ile Gly Asn Glu Asn His 660 665 670 Gly Leu Tyr Leu Ala Asp Gln Tyr Val Lys Gly Ile Ala Lys Ser Arg 675 680 685 Lys Ser 690 <210> 20 <211> 2073 <212> DNA <213> Artifical sequence <400> 20 atggaagtag taagtctgat aaccattctg ctcgtcgtca ccgtctcaaa cgctgataaa 60 atctgcatcg gctaccaatc cacaaatagc actgaaaccg tggacacgct gacagagaac 120 gatgtgccgg ttactcacac caaagaactg ttgcacaccg agcataacgg tatgctctgc 180 gccactggtt taggacatcc tcttatcctg gacacttgca ccatcgaagg tttaatttac 240 ggaaacccat cctgtgatct cttacttggt ggacgtgaat ggtcatacat tgtggagagg 300 ccttctgctg ttaatggact ttgctatcca ggcaacgtcg agaatttaga agagcttcgc 360 agcctgttct catctgccag atcctaccaa agaatccaaa tcttccctga cacaatatgg 420 aacgtaacgt acagcggtac atccaaagct tgttcagatt ctttctatag atcaatgcgc 480 tggctcactc aaaagaacaa tgcttaccca atccaagatg cccagtatac caacaatcag 540 gaaaagaaca tcctttttat gtggggaatt aatcaccctc caacggacac agtccaaact 600 aatctgtaca ctcgtaccga tacaactacc tctgtagcca cggaagagat aaaccgtaca 660 ttcaaacctt taatcggccc gaggcccttg gtgaatggtc tccaaggaag aattgactac 720 tattggtcgg ttcttaagcc gggtcagacg ctgcgtata ggagtaacgg aaatttaatc gctccctggt acggccacat tctttcgggc gaaagtcatg gtagaatatt aaagaccgat cttaagcgcg gcagctgcac ggtccaatgt cagacagaga agggcggtct gaacacgaca ttgccgttcc agaatgtatc caatacgca tttggtaact gctcgaagta tattggtatc aaaagtttga agctcgcggt gggactcaga aatgttccct cgcgtagctc caggggctta ttcggtgcaa tagcgggttt tatcgaagga ggctggtcag gactcgtggc aggatggtac 1080 ggcttccaac actctacga ccaggggcgtt ggtatggctg ccgacaggga ttcaacgcaa aaagccatcg father atctaaggtc aacaacatag tagcaaaat gaacaagcag 1260. ttgaatca ttgatcatga gttttcagaa gtggaggcta gactgaacat gatcaacaac 1320. aaaatcgacg atcaaataca ggacatctgg gcttataacg ccgaactgtt ggttctctta gagaatcaaa agaccttgga cgaacacgat gctaacgtca acaacttgta caacaaagta aagagagcac tcggatcga cgcggtgga gacggaaaag gctgtttcga gttgtatcat aagtgcgata atcagtgtat ggaaactatt cgcaacggca cctacaatag acgcaaatat 1500 caagaagaga gtaagctcga acgtcagaaa atagagggcg ttaagctgga aagcgagggt 1560 acatacaaga ttccggtgg cgacatcatc aagctgctga acgaacaggt gaacaaggag 1620 atgcagtcca gcaacctgta catgtctatg tcttcatggt gctacaccca ctcactggac 1680 ggagctggtc tgttcctgtt cgaccacgct gccgaggaat acgaacacgc caagaagctg 1740 atcatcttcc tgaacgagaa caacgtgcct gtccagctga cctccatcag cgctcccgaa 1800 cacaagttcg agggtctgac tcaaatcttc cagaaggcct acgaacacga gcagcacatc 1860 tctgaatcaa tcaacaacat cgtggaccac gctatcaaga gcaaggacca cgccactttc 1920 aacttcctgc aatggtacgt ggctgagcag cacgaggaag aggtcctgtt caaggacatc 1980 ctggacaaga tcgaactgat cggcaacgag aaccacggac tgtacctggc tgaccagtac 2040 gtcaagggca tcgccaagtc ccgcaagagc taa 2073 <210> 21 <211> 730 <212> PRT <213> Artificial sequence <400> 21 Met Glu Lys Ile Val Leu Leu Phe Ala Ile Val Ser Leu Val Lys Ser 1 5 10 15 Asp His Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val 20 25 30 Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile 35 40 45 Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asn Gly Val Lys 50 55 60 Pro Leu Ile Leu Lys Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80 Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val 85 90 95 Glu Lys Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn 100 105 110 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu 115 120 125 Lys Ile Gln Ile Ile Pro Lys Asp Ser Trp Pro Asp His Glu Ala Ser 130 135 140 Leu Gly Val Ser Ala Ala Cys Pro Tyr Gln Gly Asn Ser Ser Phe Phe 145 150 155 160 Arg Asn Val Val Trp Leu Ile Lys Lys Asp Asn Ala Tyr Pro Thr Ile 165 170 175 Lys Lys Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Ile Leu Trp 180 185 190 Trp Ile His His Pro Asn Asp Glu Ala Glu Gln Thr Arg Leu Tyr Gln 195 200 205 Asn Pro Thr Thr Tyr Val Ser Ile Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220 Leu Val Pro Lys Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly 225 230 235 240 Arg Ile Asp Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn 245 250 255 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 260 265 270 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Val Glu Tyr Gly 275 280 285 Asn Cys Asn Thr Arg Cys Gln Thr Pro Ile Gly Ala Ile Asn Ser Ser 290 295 300 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320 Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335 Pro Gln Arg Glu Gly Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile 340 345 350 Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His 355 360 365 Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln 370 375 380 Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile Ile Asp Lys 385 390 395 400 Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn Asn Leu Glu 405 410 415 Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp Gly Phe Leu Asp 420 425 430 Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg 435 440 445 Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val 450 455 460 Arg Leu Gln Leu Lys Asp Asn Ala Lys Glu Leu Gly Asn Gly Cys Phe 465 470 475 480 Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Arg Asn 485 490 495 Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg Leu Lys Arg 500 505 510 Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Ile Tyr Gln Ile 515 520 525 Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Ala Ile Met 530 535 540 Met Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser Leu Gln Cys 545 550 555 560 Arg Ile Cys Ile Ser Gly Gly Asp Ile Ile Lys Leu Leu Asn Glu Gln 565 570 575 Val Asn Lys Glu Met Gln Ser Ser Asn Leu Tyr Met Ser Met Ser Ser 580 585 590 Trp Cys Tyr Thr His Ser Leu Asp Gly Ala Gly Leu Phe Leu Phe Asp 595 600 605 His Ala Ala Glu Glu Tyr Glu His Ala Lys Lys Leu Ile Ile Phe Leu 610 615 620 Asn Glu Asn Asn Val Pro Val Gln Leu Thr Ser Ile Ser Ala Pro Glu 625 630 635 640 His Lys Phe Glu Gly Leu Thr Gln Ile Phe Gln Lys Ala Tyr Glu His 645,650,655 Glu Gln His Protein Ser Glu Ser Protein Asn Protein Val Asp Protein Protein 660,665,670 Lys Ser Lys Asp His Ala Thr Phe Asn Phe Leu Gln Trp Tyr Val Ala 675,680,685 Glu Gln His Glu Glu Glu Val Leu Phe Lys Asp Ile Leu Asp Lys Ile 690,695,700 Leu Glu With Gly Asn Glu Asn His Gly Leu Tyr Leu Asp Gln Tyr 705 710 715 720 Val Lys Gly Ile Ala Lys Ser Arg Lys Ser 725,730 <210> 22 <211> 2193 <212> DNA <213> Artificial sequence <400> 22 atggaaaaaa tcgtgctgct gttcgcaatc gtgagcctgg tgaagagtga ccatatctgt 60 atcgggtatc atgctaataa ttctactgaa caggtggata ccattatgga gagaacgtg 120 actgtgaccc acgctcagga catcctggag aaaacacata acggcaagct gtgcgatctg 180 aatggagtga aacccctgat cctgaaggac tgctcagtgg caggctggct gctgggaaac 240 cccatgtgtg atgagttcat caatgtgcct gaatggtcct acattgtgga gaagccaac 300 cctgctaatg atctgtgcta cccaggcaac ttcaatgact atgaggaact gaagcacctg 360 ctgtccagaa tcaaccattt cgaaaagatc cagatcattc ccaaggattc ttggcctgac 420 cacgaggcct cactgggtgt gagtgccgct tgtccatacc agggaaacag ctccttcttt 480 aggaatgtgg tgtggctgat taagaaagac aacgcttacc ccactatcaa gaaatcttac 540 aaaacacca accaggag tctgctgatt ctgtggtgga tccaccatcc aaacgacgag 600 ggaaagaga cacgcctgta ccagaatccc accacatatg tgagcattgg gacatccact 660 ctgaaccagc gcctggtgcc taaaatcgca actcggtcca aggtgaacgg ccagtctgga 720 cggatcgatt tcttttggac cattctgaag cctaacgacg ccatcaattt cgaatccaac 780 ggcaatttta tcgcaccaga gtacgcctac aagatcgtga aagaagaga ttctactatc 840 atgaagtcag aggtggata cgggaactgc aatacccgct gtcagacacc aatcggtgcc 900 attaactctt caatgccatt tcacaatatc catcccctga caattgggga gtgccccaag 960 tatgtgaaaa gcaacaagct ggtgctggct actggtctga gaaacagccc tcagagggag 1020 ggtaggggtc tgttcggggc tatcgcaggt tttattgagg gcggatggca gggaatggtg 1080 gatgggtggt acggttatca ccatagtaac gaacagggca gcggatacgc agccgataaa 1140 gagagtacac agaaggccat tgacggagtg actaacaaag tgaatagcat cattgacaag 1200 atgaacaccc agttcgaggc tgtggggagg gaatttaaca atctggagag aaggatcgaa 1260 aacctgaata agaaaatgga agatggcttc ctggacgtgt ggacctacaa cgcagagctg 1320 ctggtgctga tggagaatga aagaacactg gattttcacg acagcaacgt gaaaaatctg 1380 tatgataaag tgaggctcca gctgaaagac aacgccaagg aactggggaa tggttgtttc 1440 gagttttacc ataagtgcga taacgagtgt atggaatctg tgagaaatgg cacttacgac 1500 tatcctcagt attcagagga agctagactg aaaagggagg aaatttcagg ggtgaagctg 1560 gagagtatcg gtatttacca gatcctgtcc atttattcta ccgtggctag tagcctggtg 1620 ctggcaatca tgatggctgg gctgtccctg tggatgtgta gcaatggaag tctccagtgt 1680 cggatttgta tctccggtgg cgacatcatc aagctgctga acgaacaggt gaacaaggag 1740 atgcagtcca gcaacctgta catgtctatg tcttcatggt gctacaccca ctcactggac 1800 ggagctggtc tgttcctgtt cgaccacgct gccgaggaat acgaacacgc caagaagctg 1860 atcatcttcc tgaacgagaa caacgtgcct gtccagctga cctccatcag cgctcccgaa 1920 cacaagttcg agggtctgac tcaaatcttc cagaaggcct acgaacacga gcagcacatc 1980 tctgaatcaa tcaacaacat cgtggaccac gctatcaaga gcaaggacca cgccactttc 2040 aacttcctgc aatggtacgt ggctgagcag cacgaggaag aggtcctgtt caaggacatc 2100 ctggacaaga tcgaactgat cggcaacgag aaccacggac tgtacctggc tgaccagtac 2160 gtcaagggca tcgccaagtc ccgcaagagc taa 2193 <210> 23 <211> 690 <212> PRT <213> Artificial sequence <400> 23 Met Glu Val Val Ser Leu Ile Thr Ile Leu Leu Val Val Thr Val Ser 1 5 10 15 Asn Ala Asp Lys Ile Cys Ile Gly Tyr Gln Ser Thr Asn Ser Thr Glu 20 25 30 Thr Val Asp Thr Leu Thr Glu Ser Asp Val Pro Val Thr His Thr Lys 35 40 45 Glu Leu Leu His Thr Glu His Asn Gly Met Leu Cys Ala Thr Gly Leu 50 55 60 Gly His Pro Leu Ile Leu Asp Thr Cys Thr Ile Glu Gly Leu Ile Tyr 65 70 75 80 Gly Asn Pro Ser Cys Asp Leu Leu Leu Gly Gly Arg Glu Trp Ser Tyr 85 90 95 Ile Val Glu Arg Pro Ser Ala Val Asn Gly Leu Cys Tyr Pro Gly Asn 100 105 110 Val Glu Asn Leu Glu Glu Leu Arg Ser Leu Phe Ser Ser Ala Arg Ser 115 120 125 Tyr Gln Arg Ile Gln Ile Phe Pro Asp Thr Ile Trp Asn Val Thr Tyr 130 135 140 Ser Gly Thr Ser Lys Ala Cys Ser Asp Ser Phe Tyr Arg Ser Met Arg 145 150 155 160 Trp Leu Thr Gln Lys Asn Asn Ala Tyr Pro Ile Gln Asp Ala Gln Tyr 165 170 175 Thr Asn Asn Gln Glu Lys Asn Ile Leu Phe Met Trp Gly Ile His Gln 180 185 190 Pro Pro Thr Glu Thr Val Gln Thr Asn Leu Tyr Thr Arg Thr Asp Thr 195 200 205 Thr Thr Ser Val Ala Thr Glu Glu Ile Asn Arg Thr Phe Lys Pro Leu 210 215 220 Ile Gly Pro Arg Pro Leu Val Asn Gly Leu Gln Gly Arg Ile Asp Tyr 225 230 235 240 Tyr Trp Ser Val Leu Lys Pro Gly Gln Thr Leu Arg Ile Arg Ser Asn 245 250 255 Gly Asn Leu Ile Ala Pro Trp Tyr Gly His Ile Leu Ser Gly Glu Ser 260 265 270 His Gly Arg Ile Leu Lys Thr Asp Leu Lys Arg Gly Ser Cys Thr Val 275 280 285 Gln Cys Gln Thr Glu Lys Gly Gly Leu Asn Thr Thr Leu Pro Phe Gln 290 295 300 Asn Val Ser Lys Tyr Ala Phe Gly Asn Cys Ser Lys Tyr Ile Gly Ile 305 310 315 320 Lys Ser Leu Lys Leu Ala Val Gly Leu Arg Asn Val Pro Ser Arg Ser 325 330 335 Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp 340 345 350 Ser Gly Leu Val Ala Gly Trp Tyr Gly Phe Gln His Ser Asn Asp Gln 355 360 365 Gly Val Gly Met Ala Ala Asp Arg Asp Ser Thr Gln Lys Ala Ile Asp 370 375 380 Lys Ile Thr Ser Lys Val Asn Asn Ile Val Asp Lys Met Asn Lys Gln 385 390 395 400 Tyr Glu Ile Ile Asp His Glu Phe Ser Glu Val Glu Ala Arg Leu Asn 405 410 415 Met Ile Asn Asn Lys Ile Asp Asp Gln Ile Gln Asp Ile Trp Ala Tyr 420 425 430 Asn Ala Glu Leu Leu Val Leu Leu Glu Asn Gln Lys Thr Leu Asp Glu 435 440 445 His Asp Ala Asn Val Asn Asn Leu Tyr Asn Lys Val Lys Arg Ala Leu 450 455 460 Gly Ser Asn Ala Val Glu Asp Gly Lys Gly Cys Phe Glu Leu Tyr His 465 470 475 480 Lys Cys Asp Asn Gln Cys Met Glu Thr Ile Arg Asn Gly Thr Tyr Asn 485 490 495 Arg Arg Lys Tyr Gln Glu Glu Ser Lys Leu Glu Arg Gln Lys Ile Glu 500 505 510 Gly Val Lys Leu Glu Ser Glu Gly Thr Tyr Lys Ile Ser Gly Gly Asp 515 520 525 Ile Ile Lys Leu Leu Asn Glu Gln Val Asn Lys Glu Met Gln Ser Ser 530 535 540 Asn Leu Tyr Met Ser Met Ser Ser Trp Cys Tyr Thr His Ser Leu Asp 545 550 555 560 Gly Ala Gly Leu Phe Leu Phe Asp His Ala Ala Glu Glu Tyr Glu His 565 570 575 Ala Lys Lys Leu Ile Ile Phe Leu Asn Glu Asn Asn Val Pro Val Gln 580 585 590 Leu Thr Ser Ile Ser Ala Pro Glu His Lys Phe Glu Gly Leu Thr Gln 595 600 605 Ile Phe Gln Lys Ala Tyr Glu His Glu Gln His Ile Ser Glu Ser Ile 610 615 620 Asn Asn Ile Val Asp His Ala Ile Lys Ser Lys Asp His Ala Thr Phe 625 630 635 640 Asn Phe Leu Gln Trp Tyr Val Ala Glu Gln His Glu Glu Glu Val Leu 645,650,655 Phe Lys Asp Ile Leu Asp Lys Ile Glu Leu Ile Gly Asn Glu Asn His 660 665 670 Gly Leu Tyr Leu Ala Asp Gln Tyr Val Lys Gly Ile Ala Lys Ser Arg 675 680 685 Lys Ser 690 <210> 24 <211> 2073 <212> DNA <213> Artificial sequence <400> 24 atggaagtag taagtctgat aaccattctg ctcgtcgtca ccgtctcaaa cgctgataaa 60 atctgcatcg gctaccaatc cacaatagc actgaaaccg tggacacgct gacagagagt 120 gatgtgccgg ttactcacac caaagaactg ttgcacaccg agcataacgg tatgctctgc 180 gccactggtt taggacatcc tcttatcctg gacacttgca ccatcgaagg tttaatttac 240 ggaaacccat cctgtgatct cttacttggt ggacgtgaat ggtcatacat tgtggagagg 300 ccttctgctg ttaatggact ttgctatcca ggcaacgtcg agaatttaga agagcttcgc 360 agcctgttct catctgccag atcctaccaa agaatccaaa tcttccctga caaatatgg 420 aacgtaacgt acagcggtac atccaaagct tgttcagatt ctttctatag atcaatgcgc 480 tggctcactc aaaagaacaa tgcttaccca atccaagatg cccagtatac caacaatcag 540 gaaaagaaca tcctttttat gtgggggaatt caccaacctc caacggaaac agtccaaact 600 aatctgtaca ctcgtaccga tacaactacc tctgtagcca cggagaagat aaaccgtaca 660 ttcaaacctt taatcggccc gaggcccttg gtgaatggtc tccaaggaag aattgactac 720 tattggtcgg ttcttaagcc gggtcagacg ctgcgtataa ggagtaacgg aaatttaatc 780 gctccctggt acggccacat tctttcgggc gaaagtcatg gtagaatatt aaagaccgat 840 cttaagcgcg gcagctgcac ggtccaatgt cagacagaga agggcggtct gaacacgaca 900 ttgccgttcc agaatgtatc caaatacgca tttggtaact gctcgaagta tattggtatc 960 aaaagtttga agctcgcggt gggactcaga aatgttccct cgcgtagctc caggggctta 1020 ttcggtgcaa tagcgggttt tatcgaagga ggctggtcag gactcgtggc aggatggtac 1080 ggcttccaac actctaacga ccagggcgtt ggtatggctg ccgacaggga ttcaacgcaa 1140 aaagccatcg ataagataac atctaaggtc aacaacatag tagacaaaat gaacaagcag 1200 tacgaaatca ttgatcatga gttttcagaa gtggaggcta gactgaacat gatcaacaac 1260 aaaatcgacg atcaaataca ggacatctgg gcttataacg ccgaactgtt ggttctctta 1320 gagaatcaaa agaccttgga cgaacacgat gctaacgtca acaacttgta caacaaagta 1380 aagagagcac tcggatcgaa cgcggtggaa gacggaaaag gctgtttcga gttgtatcat 1440 aagtgcgata atcagtgtat ggaaactatt cgcaacggca cctacaatag acgcaaatat 1500 caagaagaga gtaagctcga acgtcagaaa atagagggcg ttaagctgga aagcgagggt 1560 acatacaaga tttccggtgg cgacatcatc aagctgctga acgaacaggt gaacaaggag 1620 atgcagtcca gcaacctgta catgtctatg tcttcatggt gctacaccca ctcactggac 1680 ggagctggtc tgttcctgtt cgaccacgct gccgaggaat acgaacacgc caagaagctg 1740 atcatcttcc tgaacgagaa caacgtgcct gtccagctga cctccatcag cgctcccgaa 1800 cacaagttcg agggtctgac tcaatctc cagaaggcct acgaacacga gcagcacacga 1860 tctgaatcaa cgtggaccac gctatcaga gcaaggacca cgccactttc 1920 aacttcctgc aatgtacgt ggctgagcag cacgaggaag aggtcctgtt caggacatc 1980 ctggacaaga tcgaacgat cggcaacgag aaccacggac tgtacctggc tgaccagtac 2040 gtcaagggca tcgccaagtc ccgcaaggc taa 2073 <210> 25 <211> 730 <212> PRT <213> Artificial sequence <400> 25 Met Glu Lys Ile Val Leu Phe Ala Ile Val Ser Leu Val Lys Ser 1 5 10 15 Asp Contains Cys Contains Gly Tyr Only Asn Asn Served Thr Glu Gln Val 20 25 30 Asp Thr Met Glu Lys Asn with Thr Value Only Gln Asp 35 40 45 To Glu Arg Thr and Gly Arg To Cys Asp To Gly Val Lys 50 55 60 Pro Leu Leu Lys Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80 Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val 85 90 95 Glu Lys Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn 100 105 110 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu 115 120 125 Lys Ile Gln Ile Ile Pro Lys Asp Ser Trp Pro Asp His Glu Ala Ser 130 135 140 Leu Gly Val Ser Ala Ala Cys Pro Tyr Gln Gly Asn Ser Ser Phe Phe 145 150 155 160 Arg Asn Val Val Trp Leu Ile Lys Lys Asp Asn Ala Tyr Pro Thr Ile 165 170 175 Lys Lys Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Ile Met Trp 180 185 190 Trp Ile His His Pro Asn Asp Glu Ala Glu Gln Thr Arg Leu Tyr Gln 195 200 205 Asn Pro Thr Thr Tyr Val Ser Ile Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220 Leu Val Pro Lys Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly 225 230 235 240 Arg Ile Asp Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn 245 250 255 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 260 265 270 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Val Glu Tyr Gly 275 280 285 Asn Cys Asn Thr Arg Cys Gln Thr Pro Ile Gly Ala Ile Asn Ser Ser 290 295 300 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320 Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335 Pro Gln Arg Glu Gly Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile 340 345 350 Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His 355 360 365 Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln 370 375 380 Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile Ile Asp Lys 385 390 395 400 Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn Asn Leu Glu 405 410 415 Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp Gly Phe Leu Asp 420 425 430 Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg 435 440 445 Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val 450 455 460 Arg Leu Gln Leu Lys Asp Asn Ala Lys Glu Leu Gly Asn Gly Cys Phe 465 470 475 480 Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Arg Asn 485 490 495 Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg Leu Lys Arg 500 505 510 Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Ile Tyr Gln Ile 515 520 525 Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Ala Ile Met 530 535 540 Met Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser Leu Gln Cys 545 550 555 560 Arg Ile Cys Ile Ser Gly Gly Asp Ile Ile Lys Leu Leu Asn Glu Gln 565 570 575 Val Asn Lys Glu Met Gln Ser Ser Asn Leu Tyr Met Ser Met Ser Ser 580 585 590 Trp Cys Tyr Thr His Ser Leu Asp Gly Ala Gly Leu Phe Leu Phe Asp 595 600 605 His Ala Ala Glu Glu Tyr Glu His Ala Lys Lys Leu Ile Ile Phe Leu 610 615 620 Asn Glu Asn Asn Val Pro Val Gln Leu Thr Ser Ile Ser Ala Pro Glu 625 630 635 640 His Lys Phe Glu Gly Leu Thr Gln Ile Phe Gln Lys Ala Tyr Glu His 645 650 655 Glu Gln His Ile Ser Glu Ser Ile Asn Asn Ile Val Asp His Ala Ile 660 665 670 Lys Ser Lys Asp His Ala Thr Phe Asn Phe Leu Gln Trp Tyr Val Ala 675 680 685 Glu Gln His Glu Glu Glu Val Leu Phe Lys Asp Ile Leu Asp Lys Ile 690 695 700 Glu Leu Ile Gly Asn Glu Asn His Gly Leu Tyr Leu Ala Asp Gln Tyr 705,710,715,720 Val Lys Gly Ile Ala Lys Ser Arg Lys Ser 725 730 <210> 26 <211> 2193 <212> DNA <213> Artificial sequence <400> 26 atggaaaaaa tcgtgctgct gttcgcaatc gtgagcctgg tgaagagtga ccatatctgt 60 atcgggtatc atgctaataa ttctactgaa caggtggata ccattatgga gaagaacatt 120 actgtgaccc acgctcagga catcctggag cgcacacata acggccgcct gtgcgatctg 180 aatggagtga aacccctgat cctgaaggac tgctcagtgg caggctggct gctgggaaac 240 cccatgtgtg atgagttcat caatgtgcct gaatggtcct acattgtgga gaaagccaac 300 cctgctaatg atctgtgcta cccaggcaac ttcaatgact atgaggaact gaagcacctg 360 ctgtccagaa tcaaccattt cgaaaagatc cagatcattc ccaaggattc ttggcctgac 420 cacgaggcct cactgggtgt gagtgccgct tgtccatacc agggaaacag ctccttcttt 480 aggaatgtgg tgtggctgat taagaaagac aacgcttacc ccactatcaa gaaatcttac 540 aaaacacca accaggag tctgctgatt agttggtgga tccaccatcc aaacgacgag 600 ggaaagaga cacgcctgta ccagaatccc accacatatg tgagcattgg gacatccact 660 ctgaaccagc gcctggtgcc taaaatcgca actcggtcca aggtgaacgg ccagtctgga 720 cggatcgatt tcttttggac cattctgaag cctaacgacg ccatcaattt cgaatccaac 780 ggcaatttta tcgcaccaga gtacgcctac aagatcgtga aagaagaga ttctactatc 840 atgaagtcag aggtggata cgggaactgc aatacccgct gtcagacacc aatcggtgcc 900 attaactctt caatgccatt tcacaatatc catcccctga caattgggga gtgccccaag 960 tatgtgaaaa gcaacaagct ggtgctggct actggtctga gaacagccc tcagagggag 1020 ggtaggggtc tgttcggggc tatcgcaggt tttattgagg gcggatggca gggaatggtg 1080 gatgggtggt acggttatca ccatagtaac gaacagggca gcggatacgc agccgataaa 1140 gagagtacac agaaggccat tgacggagtg actaacaaag tgaatagcat cattgacaag 1200 atgaacaccc agttcgaggc tgtggggagg gaatttaaca atctggagag aaggatcgaa 1260 aacctgaata agaaaatgga agatggcttc ctggacgtgt ggacctacaa cgcagagctg 1320 ctggtgctga tggagaatga aagaacactg gattttcacg acagcaacgt gaaaaatctg 1380 tatgataaag tgaggctcca gctgaaagac aacgccaagg aactggggaa tggttgtttc 1440 gagttttacc ataagtgcga taacgagtgt atggaatctg tgagaaatgg cacttacgac 1500 tatcctcagt attcagagga agctagactg aaaagggagg aaatttcagg ggtgaagctg 1560 gagagtatcg gtatttacca gatcctgtcc atttattcta ccgtggctag tagcctggtg 1620 ctggcaatca tgatggctgg gctgtccctg tggatgtgta gcaatggaag tctccagtgt 1680 cggatttgta tctccggtgg cgacatcatc aagctgctga acgaacaggt gaacaaggag 1740 atgcagtcca gcaacctgta catgtctatg tcttcatggt gctacaccca ctcactggac 1800 ggagctggtc tgttcctgtt cgaccacgct gccgaggaat acgaacacgc caagaagctg 1860 atcatcttcc tgaacgagaa caacgtgcct gtccagctga cctccatcag cgctcccgaa 1920 1980 tctgaatcaa tcaacaacat cgtggaccac gctatcaaga gcaaggacca cgccactttc 2040 aacttcctgc aatggtacgt ggctgagcag cacgaggaag aggtcctgtt caaggacatc 2100 2160 gtcaagggca tcgccaagtc ccgcaagagc taa 2193

Claims

1. A nanoantigen particle comprising a similarly sensitive sequence of a fusion protein, characterized in that, The amino acid sequence of the fusion protein is shown in SEQ ID NO.7, the amino acid sequence of the homologous sequence of the fusion protein is shown in SEQ ID NO.13, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.

14.

2. The nanoantigen particle comprising a similarly sensitive sequence of a fusion protein according to claim 1, characterized in that, The fusion protein's homologous sequence is a unit point mutant obtained by mutating the amino acid sequence shown in SEQ ID NO.13 using any one of the following amino acid unit point mutation methods: V40I, K51R, K56R, V190I, L191M, or G193W.

3. The nanoantigen particle comprising a similarly sensitive sequence of a fusion protein according to claim 1, characterized in that, The amino acid sequence of the fusion protein is a two-site mutant obtained by two-site mutation of any one of the amino acids shown in SEQ ID NO.13, namely V40I-K51R, K51R-V190I, or V190I-G193W.

4. The nanoantigen particle comprising a similarly sensitive sequence of a fusion protein according to claim 1, characterized in that, The amino acid sequence of the fusion protein is a multi-site mutant obtained by multi-site mutation of the amino acid sequence shown in SEQ ID NO.13 according to the V40I-K51R-K56R-V190I-L191M-G193W amino acid multi-site mutation method. The amino acid sequence of the multi-site mutant is shown in SEQ ID NO.25, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.

26.

5. Use of the nanoantigen particles according to any one of claims 1-4 in the preparation of influenza vaccines.

6. The use according to claim 8, characterized in that, include: The gene encoding the fusion protein of claim 1 was expressed in an Escherichia coli prokaryotic expression system, and the expressed antigen was collected and purified. Alternatively, the gene encoding the fusion protein of claim 1 can be expressed in a silkworm expression system, and the expressed antigen can be collected and purified. Alternatively, the gene encoding the same-sensitivity sequence of the fusion protein described in claim 1 can be expressed in the AcMNPV-insect cell eukaryotic expression system, and the expressed antigen can be collected and purified. Alternatively, the gene encoding the fusion protein of claim 1 can be cloned into a mammalian expression vector of baculovirus to obtain a recombinant baculovirus; the recombinant baculovirus can then be used to present the gene in vertebrate tissues to produce antigens.

7. The use according to claim 6, characterized in that, The gene encoding the similarity sequence of the fusion protein was constructed into a silkworm baculovirus expression vector and recombinant silkworm baculovirus was prepared; the recombinant silkworm baculovirus was expressed in silkworms or silkworm pupae. Alternatively, the gene encoding the fusion protein's similarity sequence can be cloned into a baculovirus transfer vector to construct a recombinant baculovirus transfer vector; the recombinant baculovirus transfer vector and baculovirus DNA can be co-transfected into insect cells to obtain recombinant baculovirus; the recombinant baculovirus can be expressed in insect cells or insect hosts to express the corresponding antigen, and then purified to obtain the final product.

8. An influenza vaccine, characterized in that, It comprises an effective amount of the nanoantigen particles as described in any one of claims 1-4 and a pharmaceutically acceptable adjuvant or carrier.